Pennsylvania (State or other jurisdiction of incorporation or organization) | 23-2229683 (I.R.S. Employer Identification No.) |
151 Farmington Avenue, Hartford, CT (Address of principal executive offices) | 06156 (Zip Code) |
Registrant’s telephone number, including area code: | (860) 273-0123 |
Large accelerated filer þ | Accelerated filer o | |
Non-accelerated filer o (Do not check if a smaller reporting company) | Smaller reporting company o | |
Table of Contents | Page | |
Part I | Financial Information | |
Item 1. | Financial Statements | 1 |
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 36 |
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 49 |
Item 4. | Controls and Procedures | 49 |
Part II | Other Information | |
Item 1. | Legal Proceedings | 49 |
Item 1A. | Risk Factors | 49 |
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 50 |
Item 4. | Mine Safety Disclosures | 50 |
Item 6. | Exhibits | 51 |
Signatures | 52 | |
Index to Exhibits | 53 |
Part I. | Financial Information |
Item 1. | Financial Statements |
For the Three Months | ||||||||||
Ended March 31, | ||||||||||
(Millions, except per common share data) | 2015 | 2014 | ||||||||
Revenue: | ||||||||||
Health care premiums | $ | 12,940.1 | $ | 11,911.7 | ||||||
Other premiums | 538.0 | 561.6 | ||||||||
Fees and other revenue (1) | 1,375.0 | 1,248.8 | ||||||||
Net investment income | 232.9 | 244.2 | ||||||||
Net realized capital gains | 8.1 | 28.5 | ||||||||
Total revenue | 15,094.1 | 13,994.8 | ||||||||
Benefits and expenses: | ||||||||||
Health care costs (2) | 10,240.5 | 9,576.3 | ||||||||
Current and future benefits | 528.1 | 578.7 | ||||||||
Operating expenses: | ||||||||||
Selling expenses | 414.9 | 402.8 | ||||||||
General and administrative expenses | 2,401.8 | 2,047.6 | ||||||||
Total operating expenses | 2,816.7 | 2,450.4 | ||||||||
Interest expense | 79.0 | 85.6 | ||||||||
Amortization of other acquired intangible assets | 63.2 | 62.2 | ||||||||
Loss on early extinguishment of long-term debt | — | 91.9 | ||||||||
Total benefits and expenses | 13,727.5 | 12,845.1 | ||||||||
Income before income taxes | 1,366.6 | 1,149.7 | ||||||||
Income taxes: | ||||||||||
Current | 647.0 | 418.5 | ||||||||
Deferred | (56.7 | ) | 61.8 | |||||||
Total income taxes | 590.3 | 480.3 | ||||||||
Net income including non-controlling interests | 776.3 | 669.4 | ||||||||
Less: Net (loss) income attributable to non-controlling interests | (1.2 | ) | 3.9 | |||||||
Net income attributable to Aetna | $ | 777.5 | $ | 665.5 | ||||||
Earnings per common share: | ||||||||||
Basic | $ | 2.22 | $ | 1.84 | ||||||
Diluted | $ | 2.20 | $ | 1.82 | ||||||
(1) | Fees and other revenue include administrative services contract member co-payments and plan sponsor reimbursements related to our mail order and specialty pharmacy operations of $24.1 million and $21.8 million (net of pharmaceutical and processing costs of $299.3 million and $275.4 million) for the three months ended March 31, 2015 and 2014, respectively. |
(2) | Health care costs have been reduced by Insured member co-payments related to our mail order and specialty pharmacy operations of $33.4 million and $30.6 million for the three months ended March 31, 2015 and 2014, respectively. |
For the Three Months | |||||||
Ended March 31, | |||||||
(Millions) | 2015 | 2014 | |||||
Net income including non-controlling interests | $ | 776.3 | $ | 669.4 | |||
Other comprehensive income (loss), net of tax: | |||||||
Previously impaired debt securities: (1) | |||||||
Net unrealized (losses) gains ($(3.4) and $1.7 pretax) | (2.2 | ) | 1.1 | ||||
Less: reclassification of gains to earnings ($2.4 and $.6 pretax) | 1.6 | .4 | |||||
Total previously impaired debt securities (1) | (3.8 | ) | .7 | ||||
All other securities: | |||||||
Net unrealized gains ($119.9 and $211.0 pretax) | 77.9 | 137.2 | |||||
Less: reclassification of losses to earnings ($(11.0) and $(5.0) pretax) | (7.2 | ) | (3.3 | ) | |||
Total all other securities | 85.1 | 140.5 | |||||
Foreign currency and derivatives: | |||||||
Net unrealized losses ($(21.4) and $(19.2) pretax) | (13.9 | ) | (12.5 | ) | |||
Less: reclassification of (losses) gains to earnings ($(1.5) and $15.6 pretax) | (1.0 | ) | 10.1 | ||||
Total foreign currency and derivatives | (12.9 | ) | (22.6 | ) | |||
Pension and other postretirement employee benefit (“OPEB”) plans: | |||||||
Less: amortization of net actuarial losses ($(16.1) and $(11.9) pretax) | (10.5 | ) | (7.7 | ) | |||
Less: amortization of prior service credit ($1.0 and $1.0 pretax) | .7 | .6 | |||||
Total pension and OPEB plans | 9.8 | 7.1 | |||||
Other comprehensive income | 78.2 | 125.7 | |||||
Comprehensive income including non-controlling interests | 854.5 | 795.1 | |||||
Less: Comprehensive (loss) income attributable to non-controlling interests | (1.2 | ) | 3.9 | ||||
Comprehensive income attributable to Aetna | $ | 855.7 | $ | 791.2 | |||
(1) | Represents unrealized (losses) gains on the non-credit related component of impaired debt securities that we do not intend to sell and subsequent changes in the fair value of any previously impaired security. |
(Unaudited) | ||||||||||
(Millions) | At March 31, 2015 | At December 31, 2014 | ||||||||
Assets: | ||||||||||
Current assets: | ||||||||||
Cash and cash equivalents | $ | 1,915.8 | $ | 1,420.4 | ||||||
Investments | 2,374.1 | 2,595.2 | ||||||||
Premiums receivable, net | 2,153.5 | 1,623.0 | ||||||||
Other receivables, net | 2,244.0 | 2,065.9 | ||||||||
Accrued investment income | 224.4 | 223.9 | ||||||||
Collateral received under securities loan agreements | 864.0 | 826.9 | ||||||||
Income taxes receivable | — | 372.7 | ||||||||
Deferred income taxes | 493.1 | 443.0 | ||||||||
Other current assets | 3,122.4 | 2,193.0 | ||||||||
Total current assets | 13,391.3 | 11,764.0 | ||||||||
Long-term investments | 22,587.6 | 22,193.9 | ||||||||
Reinsurance recoverables | 755.3 | 751.4 | ||||||||
Goodwill | 10,641.5 | 10,613.2 | ||||||||
Other acquired intangible assets, net | 1,880.4 | 1,948.3 | ||||||||
Property and equipment, net | 662.6 | 669.8 | ||||||||
Other long-term assets | 1,188.7 | 1,130.0 | ||||||||
Separate Accounts assets | 4,448.0 | 4,331.5 | ||||||||
Total assets | $ | 55,555.4 | $ | 53,402.1 | ||||||
Liabilities and shareholders’ equity: | ||||||||||
Current liabilities: | ||||||||||
Health care costs payable | $ | 6,087.2 | $ | 5,621.1 | ||||||
Future policy benefits | 699.8 | 705.9 | ||||||||
Unpaid claims | 744.7 | 745.3 | ||||||||
Unearned premiums | 627.6 | 519.5 | ||||||||
Policyholders’ funds | 2,138.9 | 1,984.5 | ||||||||
Collateral payable under securities loan and repurchase agreements | 864.0 | 1,028.6 | ||||||||
Short-term debt | 297.0 | 500.0 | ||||||||
Current portion of long-term debt | — | 229.3 | ||||||||
Income taxes payable | 322.3 | — | ||||||||
Accrued expenses and other current liabilities | 4,886.4 | 4,022.3 | ||||||||
Total current liabilities | 16,667.9 | 15,356.5 | ||||||||
Future policy benefits | 6,399.5 | 6,427.4 | ||||||||
Unpaid claims | 1,649.7 | 1,650.6 | ||||||||
Policyholders’ funds | 1,181.1 | 1,163.2 | ||||||||
Long-term debt, less current portion | 7,846.1 | 7,852.0 | ||||||||
Deferred income taxes | 914.0 | 867.5 | ||||||||
Other long-term liabilities | 1,330.2 | 1,201.6 | ||||||||
Separate Accounts liabilities | 4,448.0 | 4,331.5 | ||||||||
Total liabilities | 40,436.5 | 38,850.3 | ||||||||
Commitments and contingencies (Note 12) | ||||||||||
Shareholders’ equity: | ||||||||||
Common stock ($.01 par value; 2.5 billion shares authorized and 349.2 million shares issued | ||||||||||
and outstanding in 2015; 2.6 billion shares authorized and 349.8 million shares issued and | ||||||||||
outstanding in 2014) and additional paid-in capital | 4,539.7 | 4,542.2 | ||||||||
Retained earnings | 11,546.0 | 11,051.7 | ||||||||
Accumulated other comprehensive loss | (1,033.1 | ) | (1,111.3 | ) | ||||||
Total Aetna shareholders’ equity | 15,052.6 | 14,482.6 | ||||||||
Non-controlling interests | 66.3 | 69.2 | ||||||||
Total equity | 15,118.9 | 14,551.8 | ||||||||
Total liabilities and equity | $ | 55,555.4 | $ | 53,402.1 | ||||||
Attributable to Aetna | ||||||||||||||||||||||||||
(Millions) | Number of Common Shares Outstanding | Common Stock and Additional Paid-in Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Total Aetna Shareholders’ Equity | Non-Controlling Interests | Total Equity | |||||||||||||||||||
Three Months Ended March 31, 2015 | ||||||||||||||||||||||||||
Balance at December 31, 2014 | 349.8 | $ | 4,542.2 | $ | 11,051.7 | $ | (1,111.3 | ) | $ | 14,482.6 | $ | 69.2 | $ | 14,551.8 | ||||||||||||
Net income (loss) | — | — | 777.5 | — | 777.5 | (1.2 | ) | 776.3 | ||||||||||||||||||
Other decreases in non- | ||||||||||||||||||||||||||
controlling interest | — | — | — | — | — | (1.7 | ) | (1.7 | ) | |||||||||||||||||
Other comprehensive income (Note 6) | — | — | — | 78.2 | 78.2 | — | 78.2 | |||||||||||||||||||
Common shares issued for benefit | ||||||||||||||||||||||||||
plans, including tax benefits, net of | ||||||||||||||||||||||||||
employee tax withholdings | 1.5 | (2.4 | ) | — | — | (2.4 | ) | — | (2.4 | ) | ||||||||||||||||
Repurchases of common shares | (2.1 | ) | (.1 | ) | (196.2 | ) | — | (196.3 | ) | — | (196.3 | ) | ||||||||||||||
Dividends declared | — | — | (87.0 | ) | — | (87.0 | ) | — | (87.0 | ) | ||||||||||||||||
Balance at March 31, 2015 | 349.2 | $ | 4,539.7 | $ | 11,546.0 | $ | (1,033.1 | ) | $ | 15,052.6 | $ | 66.3 | $ | 15,118.9 | ||||||||||||
Three Months Ended March 31, 2014 | ||||||||||||||||||||||||||
Balance at December 31, 2013 | 362.2 | $ | 4,382.2 | $ | 10,555.4 | $ | (912.1 | ) | $ | 14,025.5 | $ | 52.7 | $ | 14,078.2 | ||||||||||||
Net income | — | — | 665.5 | — | 665.5 | 3.9 | 669.4 | |||||||||||||||||||
Other increases in non- | ||||||||||||||||||||||||||
controlling interest | — | — | — | — | — | .8 | .8 | |||||||||||||||||||
Other comprehensive income (Note 6) | — | — | — | 125.7 | 125.7 | — | 125.7 | |||||||||||||||||||
Common shares issued for benefit | ||||||||||||||||||||||||||
plans, including tax benefits, net of | ||||||||||||||||||||||||||
employee tax withholdings | 1.7 | 32.4 | — | — | 32.4 | — | 32.4 | |||||||||||||||||||
Repurchases of common shares | (6.5 | ) | (.1 | ) | (464.9 | ) | — | (465.0 | ) | — | (465.0 | ) | ||||||||||||||
Dividends declared | — | — | (80.5 | ) | — | (80.5 | ) | — | (80.5 | ) | ||||||||||||||||
Balance at March 31, 2014 | 357.4 | $ | 4,414.5 | $ | 10,675.5 | $ | (786.4 | ) | $ | 14,303.6 | $ | 57.4 | $ | 14,361.0 |
Three Months Ended | ||||||||||
March 31, | ||||||||||
(Millions) | 2015 | 2014 | ||||||||
Cash flows from operating activities: | ||||||||||
Net income including non-controlling interests | $ | 776.3 | $ | 669.4 | ||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
Net realized capital gains | (8.1 | ) | (28.5 | ) | ||||||
Depreciation and amortization | 164.0 | 154.7 | ||||||||
Debt fair value amortization | (7.8 | ) | (15.1 | ) | ||||||
Equity in earnings of affiliates, net | (9.7 | ) | (20.6 | ) | ||||||
Stock-based compensation expense | 49.8 | 38.8 | ||||||||
Amortization of net investment premium | 22.3 | 18.3 | ||||||||
Loss on early extinguishment of long-term debt | — | 91.9 | ||||||||
Changes in assets and liabilities: | ||||||||||
Accrued investment income | (.5 | ) | (1.5 | ) | ||||||
Premiums due and other receivables | (830.4 | ) | (337.0 | ) | ||||||
Income taxes | 629.5 | 420.3 | ||||||||
Other assets and other liabilities | 128.7 | (70.6 | ) | |||||||
Health care and insurance liabilities | 564.5 | 501.4 | ||||||||
Other, net | (5.2 | ) | .7 | |||||||
Net cash provided by operating activities | 1,473.4 | 1,422.2 | ||||||||
Cash flows from investing activities: | ||||||||||
Proceeds from sales and maturities of investments | 2,608.9 | 2,143.6 | ||||||||
Cost of investments | (2,493.9 | ) | (2,303.6 | ) | ||||||
Additions to property, equipment and software | (82.3 | ) | (93.8 | ) | ||||||
Cash used for acquisitions, net of cash acquired | (10.9 | ) | — | |||||||
Net cash provided by (used for) investing activities | 21.8 | (253.8 | ) | |||||||
Cash flows from financing activities: | ||||||||||
Repayment of long-term debt | (228.8 | ) | (839.7 | ) | ||||||
Issuance of long-term debt | — | 741.9 | ||||||||
Net repayment of short-term debt | (203.0 | ) | — | |||||||
Deposits and interest credited for investment contracts | .9 | 1.1 | ||||||||
Withdrawals of investment contracts | (8.5 | ) | (1.0 | ) | ||||||
Common shares issued under benefit plans, net | (79.9 | ) | (17.0 | ) | ||||||
Stock-based compensation tax benefits | 27.7 | 13.9 | ||||||||
(Settlements) proceeds from repurchase agreements | (201.7 | ) | 156.2 | |||||||
Common shares repurchased | (196.3 | ) | (465.0 | ) | ||||||
Dividends paid to shareholders | (87.1 | ) | (81.6 | ) | ||||||
Collateral on interest rate swaps | (21.4 | ) | (16.7 | ) | ||||||
(Distributions) contributions, non-controlling interests | (1.7 | ) | 1.3 | |||||||
Net cash used for financing activities | (999.8 | ) | (506.6 | ) | ||||||
Net increase in cash and cash equivalents | 495.4 | 661.8 | ||||||||
Cash and cash equivalents, beginning of period | 1,420.4 | 1,412.3 | ||||||||
Cash and cash equivalents, end of period | $ | 1,915.8 | $ | 2,074.1 | ||||||
Supplemental cash flow information: | ||||||||||
Interest paid | $ | 47.6 | $ | 72.9 | ||||||
Income taxes (refunded) paid | (66.8 | ) | 46.2 | |||||||
1. | Organization |
• | Health Care consists of medical, pharmacy benefit management services, dental, behavioral health and vision plans offered on both an Insured basis (where we assume all or a majority of the risk for medical and dental care costs) and an employer-funded basis (where the plan sponsor under an administrative services contract (“ASC”) assumes all or a majority of this risk) and products and services, such as Accountable Care Solutions, that complement and enhance our medical products. Medical products include point-of-service (“POS”), preferred provider organization (“PPO”), health maintenance organization (“HMO”) and indemnity benefit plans. Medical products also include health savings accounts (“HSAs”) and Aetna HealthFund®, consumer-directed health plans that combine traditional POS or PPO and/or dental coverage, subject to a deductible, with an accumulating benefit account (which may be funded by the plan sponsor and/or the member in the case of HSAs). We also offer Medicare and Medicaid products and services and other medical products, such as medical management and data analytics services, medical stop loss insurance, workers’ compensation administrative services and products that provide access to our provider network in select geographies. |
• | Group Insurance primarily includes group life insurance and group disability products. Group life insurance products are offered on an Insured basis, and include basic and supplemental group term life, group universal life, supplemental or voluntary programs and accidental death and dismemberment coverage. Group disability products consist primarily of short-term and long-term disability products (and products which combine both), which are offered to employers on both an Insured and an ASC basis, and absence management services offered to employers, which include short-term and long-term disability administration and leave management. Group Insurance also includes long-term care products that were offered primarily on an Insured basis, which provide benefits covering the cost of care in private home settings, adult day care, assisted living or nursing facilities. We no longer solicit or accept new long-term care customers. |
• | Large Case Pensions manages a variety of retirement products (including pension and annuity products) primarily for tax-qualified pension plans. These products provide a variety of funding and benefit payment distribution options and other services. Large Case Pensions also includes certain discontinued products (refer to Note 15 beginning on page 33 for additional information). |
2. | Summary of Significant Accounting Policies |
3. | Earnings Per Common Share |
(Millions, except per common share data) | 2015 | 2014 | |||||
Net income attributable to Aetna | $ | 777.5 | $ | 665.5 | |||
Weighted average shares used to compute basic EPS | 349.5 | 361.6 | |||||
Dilutive effect of outstanding stock-based compensation awards | 3.2 | 3.4 | |||||
Weighted average shares used to compute diluted EPS | 352.7 | 365.0 | |||||
Basic EPS | $ | 2.22 | $ | 1.84 | |||
Diluted EPS | $ | 2.20 | $ | 1.82 | |||
(Millions) | 2015 | 2014 | |||
Stock appreciation rights (“SARs”) (1) | 1.9 | 1.3 | |||
Other stock-based compensation awards (2) | 1.1 | 1.3 | |||
(1) | SARs are excluded from the calculation of diluted EPS if the exercise price is greater than the average market price of Aetna common shares during the period (i.e., the awards are anti-dilutive). |
(2) | Performance stock units ("PSUs"), certain market stock units ("MSUs") with performance conditions, and performance stock appreciation rights ("PSARs") are excluded from the calculation of diluted EPS if all necessary performance conditions have not been satisfied at the end of the reporting period. |
(Millions) | 2015 | 2014 | |||||
Selling expenses | $ | 414.9 | $ | 402.8 | |||
General and administrative expenses: | |||||||
Salaries and related benefits | 1,206.6 | 1,119.5 | |||||
Other general and administrative expenses (1) (2) | 1,195.2 | 928.1 | |||||
Total general and administrative expenses (3) | 2,401.8 | 2,047.6 | |||||
Total operating expenses | $ | 2,816.7 | $ | 2,450.4 | |||
(1) | The three months ended March 31, 2015 and 2014 include estimated fees mandated by the ACA comprised primarily of the health insurer fee of $218.7 million and $154.8 million, respectively, and our estimated contribution to the funding of the reinsurance program of $53.6 million and $84.9 million, respectively. Refer to Note 2 beginning on page 6 for additional information on fees mandated by the ACA. |
(2) | In the three months ended December 31, 2012, we recorded a charge of $120.0 million pretax related to the settlement of purported class action litigation regarding Aetna’s payment practices related to out-of-network health care providers. That charge included the estimated cost of legal fees of plaintiffs’ counsel and the costs of administering the settlement. In the three months ended March 31, 2014, we exercised our right to terminate the settlement agreement. As a result, we released the reserve established in connection with the settlement agreement, net of amounts due to the settlement administrator, which reduced other general and administrative expenses by $103.0 million pretax in the three months ended March 31, 2014. Refer to Note 12 beginning on page 28 for additional information on the termination of the settlement agreement. |
(3) | The three months ended March 31, 2015 include $45.6 million of transaction and integration-related costs related to the acquisitions of Coventry Health Care, Inc. (“Coventry”), the InterGlobal group (“InterGlobal”) and bSwift LLC (“bswift”). The three months ended March 31, 2014 include $63.7 million of integration-related costs related to the acquisition of Coventry. |
March 31, 2015 | December 31, 2014 | ||||||||||||||||||||||
(Millions) | Current | Long-term | Total | Current | Long-term | Total | |||||||||||||||||
Debt and equity securities available for sale | $ | 2,237.3 | $ | 19,346.5 | $ | 21,583.8 | $ | 2,463.8 | $ | 18,977.9 | $ | 21,441.7 | |||||||||||
Mortgage loans | 127.6 | 1,387.6 | 1,515.2 | 124.2 | 1,438.0 | 1,562.2 | |||||||||||||||||
Other investments | 9.2 | 1,853.5 | 1,862.7 | 7.2 | 1,778.0 | 1,785.2 | |||||||||||||||||
Total investments | $ | 2,374.1 | $ | 22,587.6 | $ | 24,961.7 | $ | 2,595.2 | $ | 22,193.9 | $ | 24,789.1 |
(Millions) | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | ||||||||||||
March 31, 2015 | ||||||||||||||||
Debt securities: | ||||||||||||||||
U.S. government securities | $ | 1,341.0 | $ | 111.4 | $ | (1.3 | ) | $ | 1,451.1 | |||||||
States, municipalities and political subdivisions | 4,582.4 | 285.9 | (7.8 | ) | 4,860.5 | |||||||||||
U.S. corporate securities | 7,961.7 | 670.1 | (14.3 | ) | 8,617.5 | |||||||||||
Foreign securities | 3,252.0 | 305.2 | (10.3 | ) | 3,546.9 | |||||||||||
Residential mortgage-backed securities | 884.8 | 32.4 | (1.9 | ) | 915.3 | |||||||||||
Commercial mortgage-backed securities | 1,301.5 | 50.5 | (.5 | ) | (1) | 1,351.5 | ||||||||||
Other asset-backed securities | 743.6 | 9.5 | (2.8 | ) | (1) | 750.3 | ||||||||||
Redeemable preferred securities | 55.2 | 12.9 | — | 68.1 | ||||||||||||
Total debt securities | 20,122.2 | 1,477.9 | (38.9 | ) | 21,561.2 | |||||||||||
Equity securities | 24.4 | 2.0 | (3.8 | ) | 22.6 | |||||||||||
Total debt and equity securities (2) | $ | 20,146.6 | $ | 1,479.9 | $ | (42.7 | ) | $ | 21,583.8 | |||||||
December 31, 2014 | ||||||||||||||||
Debt securities: | ||||||||||||||||
U.S. government securities | $ | 1,301.2 | $ | 96.3 | $ | (.6 | ) | $ | 1,396.9 | |||||||
States, municipalities and political subdivisions | 4,540.0 | 277.2 | (7.8 | ) | 4,809.4 | |||||||||||
U.S. corporate securities | 8,033.2 | 606.8 | (33.6 | ) | 8,606.4 | |||||||||||
Foreign securities | 3,343.6 | 267.0 | (18.3 | ) | 3,592.3 | |||||||||||
Residential mortgage-backed securities | 902.7 | 28.9 | (3.9 | ) | 927.7 | |||||||||||
Commercial mortgage-backed securities | 1,324.6 | 52.8 | (1.6 | ) | (1) | 1,375.8 | ||||||||||
Other asset-backed securities | 644.7 | 5.8 | (6.5 | ) | (1) | 644.0 | ||||||||||
Redeemable preferred securities | 56.8 | 12.5 | — | 69.3 | ||||||||||||
Total debt securities | 20,146.8 | 1,347.3 | (72.3 | ) | 21,421.8 | |||||||||||
Equity securities | 23.3 | .4 | (3.8 | ) | 19.9 | |||||||||||
Total debt and equity securities (2) | $ | 20,170.1 | $ | 1,347.7 | $ | (76.1 | ) | $ | 21,441.7 | |||||||
(1) | At March 31, 2015 and December 31, 2014, we held securities for which we previously recognized $15.6 million and $18.6 million, respectively, of non-credit related impairments in accumulated other comprehensive loss. These securities had a net unrealized capital gain at March 31, 2015 and December 31, 2014 of $3.3 million and $3.6 million, respectively. |
(2) | Investment risks associated with our experience-rated and discontinued products generally do not impact our operating results (refer to Note 15 beginning on page 33 for additional information on our accounting for discontinued products). At March 31, 2015, debt and equity securities with a fair value of approximately $3.7 billion, gross unrealized capital gains of $428.1 million and gross unrealized capital losses of $9.7 million and, at December 31, 2014, debt and equity securities with a fair value of approximately $3.6 billion, gross unrealized capital gains of $391.3 million and gross unrealized capital losses of $16.7 million were included in total debt and equity securities, but support our experience-rated and discontinued products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income. |
(Millions) | Fair Value | ||
Due to mature: | |||
Less than one year | $ | 1,104.5 | |
One year through five years | 5,631.9 | ||
After five years through ten years | 5,817.1 | ||
Greater than ten years | 5,990.6 | ||
Residential mortgage-backed securities | 915.3 | ||
Commercial mortgage-backed securities | 1,351.5 | ||
Other asset-backed securities | 750.3 | ||
Total | $ | 21,561.2 |
Less than 12 months | Greater than 12 months | Total (1) | |||||||||||||||||||||
(Millions) | Fair Value | Unrealized Losses | Fair Value | Unrealized Losses | Fair Value | Unrealized Losses | |||||||||||||||||
March 31, 2015 | |||||||||||||||||||||||
Debt securities: | |||||||||||||||||||||||
U.S. government securities | $ | 64.0 | $ | .9 | $ | 12.9 | $ | .4 | $ | 76.9 | $ | 1.3 | |||||||||||
States, municipalities and political subdivisions | 535.0 | 4.3 | 139.3 | 3.5 | 674.3 | 7.8 | |||||||||||||||||
U.S. corporate securities | 567.1 | 9.6 | 140.0 | 4.7 | 707.1 | 14.3 | |||||||||||||||||
Foreign securities | 304.3 | 7.3 | 72.8 | 3.0 | 377.1 | 10.3 | |||||||||||||||||
Residential mortgage-backed securities | 54.7 | .2 | 106.3 | 1.7 | 161.0 | 1.9 | |||||||||||||||||
Commercial mortgage-backed securities | 76.1 | .1 | 34.1 | .4 | 110.2 | .5 | |||||||||||||||||
Other asset-backed securities | 177.2 | 2.7 | 16.1 | .1 | 193.3 | 2.8 | |||||||||||||||||
Redeemable preferred securities | 3.0 | — | — | — | 3.0 | — | |||||||||||||||||
Total debt securities | 1,781.4 | 25.1 | 521.5 | 13.8 | 2,302.9 | 38.9 | |||||||||||||||||
Equity securities | — | — | 1.4 | 3.8 | 1.4 | 3.8 | |||||||||||||||||
Total debt and equity securities (1) | $ | 1,781.4 | $ | 25.1 | $ | 522.9 | $ | 17.6 | $ | 2,304.3 | $ | 42.7 | |||||||||||
December 31, 2014 | |||||||||||||||||||||||
Debt securities: | |||||||||||||||||||||||
U.S. government securities | $ | 20.6 | $ | .1 | $ | 19.8 | $ | .5 | $ | 40.4 | $ | .6 | |||||||||||
States, municipalities and political subdivisions | 457.4 | 2.2 | 347.4 | 5.6 | 804.8 | 7.8 | |||||||||||||||||
U.S. corporate securities | 1,074.1 | 19.9 | 515.2 | 13.7 | 1,589.3 | 33.6 | |||||||||||||||||
Foreign securities | 540.0 | 12.8 | 148.0 | 5.5 | 688.0 | 18.3 | |||||||||||||||||
Residential mortgage-backed securities | 3.9 | .1 | 166.9 | 3.8 | 170.8 | 3.9 | |||||||||||||||||
Commercial mortgage-backed securities | 181.5 | .7 | 69.0 | .9 | 250.5 | 1.6 | |||||||||||||||||
Other asset-backed securities | 373.1 | 6.1 | 21.3 | .4 | 394.4 | 6.5 | |||||||||||||||||
Redeemable preferred securities | 3.0 | — | — | — | 3.0 | — | |||||||||||||||||
Total debt securities | 2,653.6 | 41.9 | 1,287.6 | 30.4 | 3,941.2 | 72.3 | |||||||||||||||||
Equity securities | 8.0 | — | 1.4 | 3.8 | 9.4 | 3.8 | |||||||||||||||||
Total debt and equity securities (1) | $ | 2,661.6 | $ | 41.9 | $ | 1,289.0 | $ | 34.2 | $ | 3,950.6 | $ | 76.1 | |||||||||||
(1) | At March 31, 2015 and December 31, 2014, debt and equity securities in an unrealized capital loss position of $9.7 million and $16.7 million, respectively, and with related fair value of $221.4 million and $402.7 million, respectively, related to experience-rated and discontinued products. |
Supporting discontinued and experience-rated products | Supporting remaining products | Total | |||||||||||||||||||||
(Millions) | Fair Value | Unrealized Losses | Fair Value | Unrealized Losses | Fair Value | Unrealized Losses | |||||||||||||||||
Due to mature: | |||||||||||||||||||||||
Less than one year | $ | — | $ | — | $ | 27.4 | $ | .1 | $ | 27.4 | $ | .1 | |||||||||||
One year through five years | 5.5 | — | 505.7 | 4.6 | 511.2 | 4.6 | |||||||||||||||||
After five years through ten years | 112.6 | 2.3 | 656.5 | 11.7 | 769.1 | 14.0 | |||||||||||||||||
Greater than ten years | 91.6 | 3.6 | 439.1 | 11.4 | 530.7 | 15.0 | |||||||||||||||||
Residential mortgage-backed securities | — | — | 161.0 | 1.9 | 161.0 | 1.9 | |||||||||||||||||
Commercial mortgage-backed securities | 10.3 | — | 99.9 | .5 | 110.2 | .5 | |||||||||||||||||
Other asset-backed securities | — | — | 193.3 | 2.8 | 193.3 | 2.8 | |||||||||||||||||
Total | $ | 220.0 | $ | 5.9 | $ | 2,082.9 | $ | 33.0 | $ | 2,302.9 | $ | 38.9 | |||||||||||
(Millions) | 2015 | 2014 | |||||
OTTI losses on debt securities recognized in earnings | $ | (2.4 | ) | $ | (.2 | ) | |
Net realized capital gains, excluding OTTI losses on debt securities | 10.5 | 28.7 | |||||
Net realized capital gains | $ | 8.1 | $ | 28.5 |
(Millions) | 2015 | 2014 | |||||
Proceeds on sales | $ | 945.9 | $ | 1,092.8 | |||
Gross realized capital gains | 24.9 | 24.6 | |||||
Gross realized capital losses | 8.8 | 13.0 | |||||
(Millions) | 2015 | 2014 | |||||
New mortgage loans | $ | 12.7 | $ | 33.9 | |||
Mortgage loans fully repaid | 39.5 | 19.8 | |||||
Mortgage loans foreclosed | 9.0 | — | |||||
(In Millions, except credit ratings indicator) | March 31, 2015 | December 31, 2014 | |||||
1 | $ | 58.7 | $ | 59.7 | |||
2 to 4 | 1,416.2 | 1,443.4 | |||||
5 | 13.3 | 18.6 | |||||
6 and 7 | 27.0 | 40.5 | |||||
Total | $ | 1,515.2 | $ | 1,562.2 | |||
(Millions) | 2015 | 2014 | |||||
Debt securities | $ | 196.4 | $ | 198.1 | |||
Mortgage loans | 21.9 | 23.9 | |||||
Other investments | 23.9 | 30.1 | |||||
Gross investment income | 242.2 | 252.1 | |||||
Investment expenses | (9.3 | ) | (7.9 | ) | |||
Net investment income (1) | $ | 232.9 | $ | 244.2 | |||
(1) | Net investment income includes $66.6 million and $80.4 million for the three months ended March 31, 2015 and 2014, respectively, related to investments supporting our experience-rated and discontinued products. |
Net Unrealized Gains (Losses) | Pension and OPEB Plans | Total Accumulated Other Comprehensive (Loss) Income | ||||||||||||||||||||||||||
Securities | Foreign Currency and Derivatives | |||||||||||||||||||||||||||
(Millions) | Previously Impaired (1) | All Other | Unrecognized Net Actuarial Losses | Unrecognized Prior Service Credit | ||||||||||||||||||||||||
Three months ended March 31, 2015 | ||||||||||||||||||||||||||||
Balance at December 31, 2014 | $ | 34.9 | $ | 568.0 | $ | (60.9 | ) | $ | (1,670.9 | ) | $ | 17.6 | $ | (1,111.3 | ) | |||||||||||||
Other comprehensive (loss) income | ||||||||||||||||||||||||||||
before reclassifications | (2.2 | ) | 77.9 | (13.9 | ) | — | — | 61.8 | ||||||||||||||||||||
Amounts reclassified from accumulated | ||||||||||||||||||||||||||||
other comprehensive income | (1.6 | ) | (2 | ) | 7.2 | (2 | ) | 1.0 | (3 | ) | 10.5 | (4 | ) | (.7 | ) | (4 | ) | 16.4 | ||||||||||
Other comprehensive (loss) income | (3.8 | ) | 85.1 | (12.9 | ) | 10.5 | (.7 | ) | 78.2 | |||||||||||||||||||
Balance at March 31, 2015 | $ | 31.1 | $ | 653.1 | $ | (73.8 | ) | $ | (1,660.4 | ) | $ | 16.9 | $ | (1,033.1 | ) | |||||||||||||
Three months ended March 31, 2014 | ||||||||||||||||||||||||||||
Balance at December 31, 2013 | $ | 34.2 | $ | 326.8 | $ | .4 | $ | (1,293.8 | ) | $ | 20.3 | $ | (912.1 | ) | ||||||||||||||
Other comprehensive income (loss) | ||||||||||||||||||||||||||||
before reclassifications | 1.1 | 137.2 | (12.5 | ) | — | — | 125.8 | |||||||||||||||||||||
Amounts reclassified from accumulated | ||||||||||||||||||||||||||||
other comprehensive income | (.4 | ) | (2 | ) | 3.3 | (2 | ) | (10.1 | ) | (3 | ) | 7.7 | (4 | ) | (.6 | ) | (4 | ) | (.1 | ) | ||||||||
Other comprehensive income (loss) | .7 | 140.5 | (22.6 | ) | 7.7 | (.6 | ) | 125.7 | ||||||||||||||||||||
Balance at March 31, 2014 | $ | 34.9 | $ | 467.3 | $ | (22.2 | ) | $ | (1,286.1 | ) | $ | 19.7 | $ | (786.4 | ) | |||||||||||||
(1) | Represents unrealized gains on the non-credit related component of impaired debt securities that we do not intend to sell and subsequent changes in the fair value of any previously impaired security. |
(2) | Reclassifications out of accumulated other comprehensive income for previously impaired debt securities and all other securities are reflected in net realized capital gains (losses) within the Consolidated Statements of Income. |
(3) | Reclassifications out of accumulated other comprehensive income for foreign currency gains (losses) and derivatives are reflected in net realized capital gains (losses) within the Consolidated Statements of Income, except for the effective portion of derivatives related to interest rate swaps which are reflected in interest expense and were not material during the three months ended March 31, 2015 or 2014. Refer to Note 9 of Condensed Notes to Consolidated Financial Statements beginning on page 26 for additional information. |
(4) | Reclassifications out of accumulated other comprehensive income for pension and OPEB plan expenses are reflected in general and administrative expenses within the Consolidated Statements of Income. Refer to Note 8 of Condensed Notes to Consolidated Financial Statements beginning on page 25 for additional information. |
◦ | Level 1 – Unadjusted quoted prices for identical assets or liabilities in active markets. |
◦ | Level 2 – Inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, inputs that are observable that are not prices (such as interest rates and credit risks) and inputs that are derived from or corroborated by observable markets. |
◦ | Level 3 – Developed from unobservable data, reflecting our own assumptions. |
(Millions) | Level 1 | Level 2 | Level 3 | Total | |||||||||||
March 31, 2015 | |||||||||||||||
Assets: | |||||||||||||||
Debt securities: | |||||||||||||||
U.S. government securities | $ | 1,253.9 | $ | 197.2 | $ | — | $ | 1,451.1 | |||||||
States, municipalities and political subdivisions | — | 4,859.4 | 1.1 | 4,860.5 | |||||||||||
U.S. corporate securities | — | 8,561.4 | 56.1 | 8,617.5 | |||||||||||
Foreign securities | — | 3,515.1 | 31.8 | 3,546.9 | |||||||||||
Residential mortgage-backed securities | — | 915.3 | — | 915.3 | |||||||||||
Commercial mortgage-backed securities | — | 1,344.0 | 7.5 | 1,351.5 | |||||||||||
Other asset-backed securities | — | 708.5 | 41.8 | 750.3 | |||||||||||
Redeemable preferred securities | — | 64.0 | 4.1 | 68.1 | |||||||||||
Total debt securities | 1,253.9 | 20,164.9 | 142.4 | 21,561.2 | |||||||||||
Equity securities | 1.8 | — | 20.8 | 22.6 | |||||||||||
Derivatives | — | .3 | — | .3 | |||||||||||
Total | $ | 1,255.7 | $ | 20,165.2 | $ | 163.2 | $ | 21,584.1 | |||||||
Liabilities: | |||||||||||||||
Derivatives | $ | — | $ | 69.5 | $ | — | $ | 69.5 | |||||||
December 31, 2014 | |||||||||||||||
Assets: | |||||||||||||||
Debt securities: | |||||||||||||||
U.S. government securities | $ | 1,198.4 | $ | 198.5 | $ | — | $ | 1,396.9 | |||||||
States, municipalities and political subdivisions | — | 4,808.2 | 1.2 | 4,809.4 | |||||||||||
U.S. corporate securities | — | 8,548.2 | 58.2 | 8,606.4 | |||||||||||
Foreign securities | — | 3,560.7 | 31.6 | 3,592.3 | |||||||||||
Residential mortgage-backed securities | — | 927.7 | — | 927.7 | |||||||||||
Commercial mortgage-backed securities | — | 1,368.3 | 7.5 | 1,375.8 | |||||||||||
Other asset-backed securities | — | 602.5 | 41.5 | 644.0 | |||||||||||
Redeemable preferred securities | — | 65.2 | 4.1 | 69.3 | |||||||||||
Total debt securities | 1,198.4 | 20,079.3 | 144.1 | 21,421.8 | |||||||||||
Equity securities | 1.8 | — | 18.1 | 19.9 | |||||||||||
Derivatives | — | .3 | — | .3 | |||||||||||
Total | $ | 1,200.2 | $ | 20,079.6 | $ | 162.2 | $ | 21,442.0 | |||||||
Liabilities: | |||||||||||||||
Derivatives | $ | — | $ | 53.4 | $ | — | $ | 53.4 |
Carrying Value | Estimated Fair Value | |||||||||||||||
(Millions) | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
March 31, 2015 | ||||||||||||||||
Assets: | ||||||||||||||||
Mortgage loans | $ | 1,515.2 | $ | — | $ | — | $ | 1,581.6 | $ | 1,581.6 | ||||||
Bank loans | 233.5 | — | 223.2 | 9.3 | 232.5 | |||||||||||
Equity securities (1) | 34.9 | N/A | N/A | N/A | N/A | |||||||||||
Liabilities: | ||||||||||||||||
Investment contract liabilities: | ||||||||||||||||
With a fixed maturity | 8.9 | — | — | 8.9 | 8.9 | |||||||||||
Without a fixed maturity | 548.8 | — | — | 542.0 | 542.0 | |||||||||||
Long-term debt | 7,846.1 | — | 8,781.8 | — | 8,781.8 | |||||||||||
December 31, 2014 | ||||||||||||||||
Assets: | ||||||||||||||||
Mortgage loans | $ | 1,562.2 | $ | — | $ | — | $ | 1,621.4 | $ | 1,621.4 | ||||||
Bank loans | 231.2 | — | 217.6 | 9.4 | 227.0 | |||||||||||
Equity securities (1) | 34.9 | N/A | N/A | N/A | N/A | |||||||||||
Liabilities: | ||||||||||||||||
Investment contract liabilities: | ||||||||||||||||
With a fixed maturity | 16.6 | — | — | 16.6 | 16.6 | |||||||||||
Without a fixed maturity | 557.5 | — | — | 551.5 | 551.5 | |||||||||||
Long-term debt | 8,081.3 | — | 8,764.8 | — | 8,764.8 | |||||||||||
(1) | It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. |
March 31, 2015 | December 31, 2014 | ||||||||||||||||||||||||||||||
(Millions) | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||
Debt securities | $ | 698.2 | $ | 2,740.3 | $ | 3.5 | $ | 3,442.0 | $ | 876.0 | $ | 2,495.0 | $ | 2.9 | $ | 3,373.9 | |||||||||||||||
Equity securities | 179.9 | 5.9 | — | 185.8 | 173.3 | 5.7 | — | 179.0 | |||||||||||||||||||||||
Derivatives | — | (1.1 | ) | — | (1.1 | ) | — | .2 | — | .2 | |||||||||||||||||||||
Common/collective trusts | — | 595.9 | — | 595.9 | — | 574.0 | — | 574.0 | |||||||||||||||||||||||
Total (1) | $ | 878.1 | $ | 3,341.0 | $ | 3.5 | $ | 4,222.6 | $ | 1,049.3 | $ | 3,074.9 | $ | 2.9 | $ | 4,127.1 | |||||||||||||||
(1) | Excludes $225.4 million and $204.4 million of cash and cash equivalents and other receivables at March 31, 2015 and December 31, 2014, respectively. |
Gross Amounts of Recognized Assets (1) | Gross Amounts Not Offset in the Balance Sheets | |||||||||||
Financial Instruments | Cash Collateral Received | |||||||||||
(Millions) | Net Amount | |||||||||||
March 31, 2015 | ||||||||||||
Derivatives | $ | .3 | $ | 10.7 | $ | — | $ | 11.0 | ||||
Total | $ | .3 | $ | 10.7 | $ | — | $ | 11.0 | ||||
December 31, 2014 | ||||||||||||
Derivatives | $ | .3 | $ | 10.2 | $ | — | $ | 10.5 | ||||
Total | $ | .3 | $ | 10.2 | $ | — | $ | 10.5 | ||||
Gross Amounts of Recognized Liabilities (1) | Gross Amounts Not Offset in the Balance Sheets | |||||||||||
Financial Instruments | Cash Collateral Paid | |||||||||||
(Millions) | Net Amount | |||||||||||
March 31, 2015 | ||||||||||||
Derivatives | $ | 69.5 | $ | 1.3 | $ | (70.4 | ) | $ | .4 | |||
Securities lending | 864.0 | (864.0 | ) | — | — | |||||||
Total | $ | 933.5 | $ | (862.7 | ) | $ | (70.4 | ) | $ | .4 | ||
December 31, 2014 | ||||||||||||
Derivatives | $ | 53.4 | $ | .9 | $ | (49.0 | ) | $ | 5.3 | |||
Securities lending | 826.9 | (826.9 | ) | — | — | |||||||
Repurchase agreements | 201.7 | — | — | 201.7 | ||||||||
Total | $ | 1,082.0 | $ | (826.0 | ) | $ | (49.0 | ) | $ | 207.0 | ||
Pension Plans | OPEB Plans | ||||||||||||||
(Millions) | 2015 | 2014 | 2015 | 2014 | |||||||||||
Service cost | $ | — | $ | — | $ | — | $ | — | |||||||
Amortization of prior service credit | (.1 | ) | (.1 | ) | (.9 | ) | (.9 | ) | |||||||
Interest cost | 65.2 | 72.1 | 2.7 | 3.0 | |||||||||||
Expected return on plan assets | (104.8 | ) | (105.6 | ) | (.8 | ) | (.8 | ) | |||||||
Recognized net actuarial losses | 15.4 | 11.7 | .7 | .2 | |||||||||||
Net periodic benefit (income) cost | $ | (24.3 | ) | $ | (21.9 | ) | $ | 1.7 | $ | 1.5 | |||||
(Millions) | March 31, 2015 | December 31, 2014 | |||||
Senior notes, 6.125%, due 2015 (1) | $ | — | $ | 229.3 | |||
Senior notes, 5.95%, due 2017 | 414.3 | 418.3 | |||||
Senior notes, 1.75%, due 2017 | 249.3 | 249.2 | |||||
Senior notes, 1.5%, due 2017 | 498.8 | 498.6 | |||||
Senior notes, 2.2%, due 2019 | 374.7 | 374.7 | |||||
Senior notes, 3.95%, due 2020 | 745.4 | 745.2 | |||||
Senior notes, 5.45%, due 2021 | 685.2 | 688.6 | |||||
Senior notes, 4.125%, due 2021 | 495.7 | 495.5 | |||||
Senior notes, 2.75%, due 2022 | 987.2 | 986.8 | |||||
Senior notes, 3.5%, due 2024 | 747.0 | 746.9 | |||||
Senior notes, 6.625%, due 2036 | 769.8 | 769.8 | |||||
Senior notes, 6.75%, due 2037 | 530.8 | 530.7 | |||||
Senior notes, 4.5%, due 2042 | 480.9 | 480.8 | |||||
Senior notes, 4.125%, due 2042 | 492.9 | 492.8 | |||||
Senior notes, 4.75%, due 2044 | 374.1 | 374.1 | |||||
Total long-term debt | 7,846.1 | 8,081.3 | |||||
Less current portion of long-term debt | — | 229.3 | |||||
Total long-term debt, less current portion | $ | 7,846.1 | $ | 7,852.0 | |||
(1) | The 6.125% senior notes were repaid in January 2015. These notes were classified as current in the consolidated balance sheet as of December 31, 2014. |
Trade Date: | Value of Repurchase Program (Millions) | Repurchase Period | Number of Shares Repurchased (Millions) | |||
December 15, 2014 | $ | 150.0 | January and February 2015 | 1.6 | ||
Date Declared | Dividend Amount Per Share | Stockholders of Record Date | Date Paid/ To be Paid | Total Dividends (Millions) | ||||||
February 27, 2015 | $ | .25 | April 9, 2015 | April 24, 2015 | $ | 87.3 | ||||
2015 | 2014 | ||||||
Expected term (in years) | 6.48 | 5.72 | |||||
Volatility | 33.4 | % | 35.8 | % | |||
Risk-free interest rate | 1.81 | % | 1.74 | % | |||
Dividend yield | 1.13 | % | 1.36 | % | |||
Initial price | $ | 100.50 | $ | 72.26 | |||
(Millions) | Health Care | Group Insurance | Large Case Pensions | Corporate Financing | Total Company | ||||||||||||||
Three Months Ended March 31, 2015 | |||||||||||||||||||
Revenue from external customers | $ | 14,285.8 | $ | 554.5 | $ | 12.8 | $ | — | $ | 14,853.1 | |||||||||
Operating earnings (loss) (1) | 835.6 | 43.9 | 2.1 | (37.3 | ) | 844.3 | |||||||||||||
Three Months Ended March 31, 2014 | |||||||||||||||||||
Revenue from external customers | $ | 13,131.4 | $ | 544.4 | $ | 46.3 | $ | — | $ | 13,722.1 | |||||||||
Operating earnings (loss) (1) | 719.0 | 41.2 | 4.8 | (43.0 | ) | 722.0 | |||||||||||||
(1) | Operating earnings (loss) excludes net realized capital gains or losses, amortization of other acquired intangible assets and the other items described in the reconciliation below. |
(Millions) | 2015 | 2014 | |||||
Operating earnings (1) | $ | 844.3 | $ | 722.0 | |||
Transaction and integration-related costs, net of tax | (30.7 | ) | (41.9 | ) | |||
Loss on early extinguishment of long-term debt, net of tax | — | (59.7 | ) | ||||
Release of litigation-related reserve, net of tax | — | 67.0 | |||||
Amortization of other acquired intangible assets, net of tax | (41.1 | ) | (40.4 | ) | |||
Net realized capital gains, net of tax | 5.0 | 18.5 | |||||
Net income attributable to Aetna | $ | 777.5 | $ | 665.5 | |||
(1) | In addition to net realized capital gains and amortization of other acquired intangible assets, the following other items are excluded from operating earnings because we believe they neither relate to the ordinary course of our business nor reflect our underlying business performance: |
• | We incurred transaction and integration-related costs of $30.7 million ($45.6 million pretax) during the three months ended March 31, 2015, related to the acquisitions of Coventry, InterGlobal and bswift, and integration-related costs of $41.9 million ($63.7 million pretax) during the three months ended March 31, 2014, related to the acquisition of Coventry. Transaction costs include advisory, legal and other professional fees which are not deductible for tax purposes and are reflected in our GAAP Consolidated Statements of Income in general and administrative expenses. |
• | We incurred a loss on the early extinguishment of long-term debt of $59.7 million ($91.9 million pretax) during the three months ended March 31, 2014 related to the redemption of our 6.0% senior notes due 2016. |
• | We recorded a charge of $78.0 million ($120.0 million pretax) during the three months ended December 31, 2012 related to the settlement of purported class action litigation regarding our payment practices related to out-of-network health care providers. That charge included the estimated cost of legal fees of plaintiffs’ counsel and the costs of administering the settlement. During the three months ended March 31, 2014, we exercised our right to terminate the settlement agreement. As a result, we released the reserve established in connection with the settlement agreement, net of amounts due to the settlement administrator, which reduced other general and administrative expenses by $67.0 million ($103.0 million pretax) in the three months ended March 31, 2014. Refer to Note 12 beginning on page 28 for additional information on the termination of the settlement agreement. |
15. | Discontinued Products |
(Millions) | 2015 | 2014 | |||||
Reserve, beginning of period | $ | 1,014.7 | $ | 979.5 | |||
Operating income | 3.1 | 5.8 | |||||
Net realized capital gains | 19.0 | 6.3 | |||||
Reserve, end of period | $ | 1,036.8 | $ | 991.6 |
(Millions) | 2015 | 2014 | |||||
Assets: | |||||||
Debt and equity securities available for sale | $ | 2,384.2 | $ | 2,376.2 | |||
Mortgage loans | 349.8 | 386.8 | |||||
Other investments | 706.5 | 662.2 | |||||
Total investments | 3,440.5 | 3,425.2 | |||||
Other assets | 93.1 | 112.9 | |||||
Collateral received under securities loan agreements | 201.2 | 200.7 | |||||
Receivable from continuing products (2) | 575.2 | 566.5 | |||||
Total assets | $ | 4,310.0 | $ | 4,305.3 | |||
Liabilities: | |||||||
Future policy benefits | $ | 2,603.3 | $ | 2,645.8 | |||
Reserve for anticipated future losses on discontinued products | 1,036.8 | 1,014.7 | |||||
Collateral payable under securities loan agreements | 201.2 | 200.7 | |||||
Current and deferred income taxes | 24.8 | 27.9 | |||||
Other liabilities (3) | 443.9 | 416.2 | |||||
Total liabilities | $ | 4,310.0 | $ | 4,305.3 | |||
(1) | Assets supporting the discontinued products are distinguished from assets supporting continuing products. |
(2) | At the time of discontinuance, a receivable from Large Case Pensions’ continuing products was established on the discontinued products balance sheet. This receivable represented the net present value of anticipated cash shortfalls in the discontinued products, which will be funded from continuing products. Interest on the receivable is accrued at the discount rate that was used to calculate the reserve. The offsetting payable, on which interest is similarly accrued, is reflected in continuing products. Interest on the payable generally offsets investment income on the assets available to fund the shortfall. These amounts are eliminated in consolidation. |
(3) | Net unrealized capital gains on the available-for-sale debt securities are included in other liabilities and are not reflected in consolidated shareholders’ equity. |
(Millions, except where indicated) | 2015 | 2014 | |||||
Total revenue | $ | 15,094.1 | $ | 13,994.8 | |||
Net income attributable to Aetna | 777.5 | 665.5 | |||||
Operating earnings (1) | 844.3 | 722.0 | |||||
Total medical membership (in thousands) | 23,670 | 22,719 | |||||
Cash flows from operations | 1,473.4 | 1,422.2 | |||||
(1) | Our discussion of operating results is based on operating earnings, which is a non-GAAP measure of net income attributable to Aetna (the term “GAAP” refers to U.S. generally accepted accounting principles). Non-GAAP financial measures we disclose, such as operating earnings, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. Refer to “Segment Results and Use of Non-GAAP Measures in this Document” beginning on page 37 for a discussion of non-GAAP measures. Refer to Note 13 of Condensed Notes to Consolidated Financial Statements beginning on page 32 for a reconciliation of our operating earnings to net income attributable to Aetna. |
• | The repayment of the entire $229 million aggregate principal amount of our 6.125% senior notes due January 2015; |
• | Repurchases of shares of our common stock of approximately $196 million; and |
• | The payment of cash dividends to shareholders of approximately $87 million. |
(Millions) | 2015 | 2014 | |||||
Premiums: | |||||||
Commercial | $ | 7,209.7 | $ | 6,814.6 | |||
Government | 5,730.4 | 5,097.1 | |||||
Total premiums | 12,940.1 | 11,911.7 | |||||
Fees and other revenue | 1,345.7 | 1,219.7 | |||||
Net investment income | 97.5 | 86.9 | |||||
Net realized capital gains | 4.6 | 26.7 | |||||
Total revenue | 14,387.9 | 13,245.0 | |||||
Health care costs | 10,240.5 | 9,576.3 | |||||
Operating expenses: | |||||||
Selling expenses | 386.3 | 374.3 | |||||
General and administrative expenses | 2,335.9 | 1,984.4 | |||||
Total operating expenses | 2,722.2 | 2,358.7 | |||||
Amortization of other acquired intangible assets | 63.2 | 61.1 | |||||
Total benefits and expenses | 13,025.9 | 11,996.1 | |||||
Income before income taxes | 1,362.0 | 1,248.9 | |||||
Income taxes | 597.7 | 525.2 | |||||
Net income including non-controlling interests | 764.3 | 723.7 | |||||
Less: Net (loss) income attributable to non-controlling interests | (2.2 | ) | 2.0 | ||||
Net income attributable to Aetna | $ | 766.5 | $ | 721.7 | |||
(Millions) | 2015 | 2014 | |||||
Net income attributable to Aetna | $ | 766.5 | $ | 721.7 | |||
Transaction and integration-related costs, net of tax | 30.7 | 41.9 | |||||
Release of litigation-related reserve, net of tax | — | (67.0 | ) | ||||
Amortization of other acquired intangible assets, net of tax | 41.1 | 39.7 | |||||
Net realized capital gains, net of tax | (2.7 | ) | (17.3 | ) | |||
Operating earnings | $ | 835.6 | $ | 719.0 | |||
(1) | In addition to net realized capital gains and amortization of other acquired intangible assets, the following other items are excluded from operating earnings because we believe they neither relate to the ordinary course of our business nor reflect our underlying business performance: |
• | During the three months ended March 31, 2015, we incurred transaction and integration-related costs related to the acquisitions of Coventry, InterGlobal and bswift of $30.7 million ($45.6 million pretax), all of which was recorded in our Health Care segment. During the three months ended March 31, 2014, we incurred integration-related costs related to the acquisition of Coventry of $41.9 million ($63.7 million pretax), all of which was recorded in our Health Care segment. Transaction costs include advisory, legal and other professional fees which are not deductible for tax purposes and are reflected in our GAAP Consolidated Statements of Income in general and administrative expenses. |
• | We recorded a charge of $78.0 million ($120.0 million pretax) during the three months ended December 31, 2012 related to the settlement of purported class action litigation regarding Aetna’s payment practices related to out-of-network health care providers. That charge included the estimated cost of legal fees of plaintiffs’ counsel and the costs of administering the settlement. During the three months ended March 31, 2014, we exercised our right to terminate the settlement agreement. As a result, we released the reserve established in connection with the settlement agreement, net of amounts due to the settlement administrator, which reduced other general and administrative expenses by $67.0 million ($103.0 million pretax) in the three months ended March 31, 2014. Refer to Note 12 beginning on page 28 for additional information on the termination of the settlement agreement. |
2015 | 2014 | ||||
Commercial | 77.4 | % | 77.2 | % | |
Government | 81.3 | % | 84.7 | % | |
Total | 79.1 | % | 80.4 | % |
2015 | 2014 | ||||||||||||||||
(Thousands) | Insured | ASC | Total | Insured | ASC | Total | |||||||||||
Medical: | |||||||||||||||||
Commercial | 6,363 | 13,496 | 19,859 | 6,046 | 13,180 | 19,226 | |||||||||||
Medicare Advantage | 1,228 | — | 1,228 | 1,101 | — | 1,101 | |||||||||||
Medicare Supplement | 488 | — | 488 | 417 | — | 417 | |||||||||||
Medicaid (1) | 1,338 | 757 | 2,095 | 1,280 | 695 | 1,975 | |||||||||||
Total Medical Membership | 9,417 | 14,253 | 23,670 | 8,844 | 13,875 | 22,719 | |||||||||||
Consumer-Directed Health Plans (2) | 3,981 | 3,528 | |||||||||||||||
Dually-Eligible for Medicare and Medicaid (1) | 23 | — | |||||||||||||||
Dental: | |||||||||||||||||
Total Dental Membership | 6,182 | 9,373 | 15,555 | 5,842 | 8,723 | 14,565 | |||||||||||
Pharmacy: | |||||||||||||||||
Commercial | 10,789 | 10,525 | |||||||||||||||
Medicare PDP (stand-alone) | 1,435 | 1,632 | |||||||||||||||
Medicare Advantage PDP | 850 | 725 | |||||||||||||||
Medicaid (1) | 2,351 | 1,301 | |||||||||||||||
Total Pharmacy Benefit Management Services | 15,425 | 14,183 | |||||||||||||||
(1) | Medicaid membership includes members who are dually-eligible for both Medicare and Medicaid. |
(2) | Represents members in consumer-directed health plans who also are included in Commercial medical membership above. |
(Millions) | 2015 | 2014 | |||||
Health care costs payable, beginning of period | $ | 5,621.1 | $ | 4,547.4 | |||
Less: reinsurance recoverables | 5.8 | 8.5 | |||||
Health care costs payable, beginning of period, net | 5,615.3 | 4,538.9 | |||||
Add: Components of incurred health care costs: | |||||||
Current year | 10,893.6 | 10,112.1 | |||||
Prior years | (653.1 | ) | (535.8 | ) | |||
Total incurred health care costs | 10,240.5 | 9,576.3 | |||||
Less: Claims paid | |||||||
Current year | 5,929.8 | 5,754.9 | |||||
Prior years | 3,841.5 | 3,360.3 | |||||
Total claims paid | 9,771.3 | 9,115.2 | |||||
Health care costs payable, end of period, net | 6,084.5 | 5,000.0 | |||||
Add: reinsurance recoverables | 2.7 | 7.2 | |||||
Health care costs payable, end of period | $ | 6,087.2 | $ | 5,007.2 | |||
(Millions) | 2015 | 2014 | |||||
Premiums: | |||||||
Life | $ | 301.8 | $ | 304.1 | |||
Disability | 214.7 | 202.6 | |||||
Long-term care | 11.1 | 11.0 | |||||
Total premiums | 527.6 | 517.7 | |||||
Fees and other revenue | 26.9 | 26.7 | |||||
Net investment income | 62.5 | 67.6 | |||||
Net realized capital gains | 2.9 | 2.9 | |||||
Total revenue | 619.9 | 614.9 | |||||
Current and future benefits | 448.1 | 451.8 | |||||
Operating expenses: | |||||||
Selling expenses | 28.6 | 28.5 | |||||
General and administrative expenses | 84.4 | 79.6 | |||||
Total operating expenses | 113.0 | 108.1 | |||||
Amortization of other acquired intangible assets | — | 1.1 | |||||
Total benefits and expenses | 561.1 | 561.0 | |||||
Income before income taxes | 58.8 | 53.9 | |||||
Income taxes | 13.0 | 11.5 | |||||
Net income attributable to Aetna | $ | 45.8 | $ | 42.4 | |||
(Millions) | 2015 | 2014 | |||||
Net income attributable to Aetna | $ | 45.8 | $ | 42.4 | |||
Amortization of other acquired intangible assets, net of tax | — | .7 | |||||
Net realized capital gains, net of tax | (1.9 | ) | (1.9 | ) | |||
Operating earnings | $ | 43.9 | $ | 41.2 | |||
(Millions) | 2015 | 2014 | |||||
Premiums | $ | 10.4 | $ | 43.9 | |||
Net investment income | 72.9 | 89.7 | |||||
Other revenue | 2.4 | 2.4 | |||||
Net realized capital gains (losses) | .6 | (1.1 | ) | ||||
Total revenue | 86.3 | 134.9 | |||||
Current and future benefits | 80.0 | 126.9 | |||||
General and administrative expenses | 3.1 | 3.0 | |||||
Total benefits and expenses | 83.1 | 129.9 | |||||
Income before income tax benefits | 3.2 | 5.0 | |||||
Income tax benefits | (.3 | ) | (1.0 | ) | |||
Net income including non-controlling interests | 3.5 | 6.0 | |||||
Less: Net income attributable to non-controlling interests | 1.0 | 1.9 | |||||
Net income attributable to Aetna | $ | 2.5 | $ | 4.1 | |||
(Millions) | 2015 | 2014 | |||||
Net income attributable to Aetna | $ | 2.5 | $ | 4.1 | |||
Net realized capital (gains) losses, net of tax | (.4 | ) | .7 | ||||
Operating earnings | $ | 2.1 | $ | 4.8 | |||
(Millions) | March 31, 2015 | December 31, 2014 | |||||
Experience-rated products (1) | $ | 1,478.4 | $ | 1,492.4 | |||
Discontinued products (1) | 3,440.5 | 3,425.2 | |||||
Remaining products | 20,042.8 | 19,871.5 | |||||
Total investments | $ | 24,961.7 | $ | 24,789.1 | |||
(1) | Investment risks associated with our experience-rated and discontinued products generally do not impact our operating results. |
(Millions) | 2015 | 2014 | |||||
Scheduled contract maturities and benefit payments (1) | $ | 20.2 | $ | 58.3 | |||
Contract holder withdrawals other than scheduled contract | |||||||
maturities and benefit payments | 8.8 | 1.2 | |||||
Participant-directed withdrawals | 1.0 | 1.1 | |||||
(1) | Includes payments made upon contract maturity and other amounts distributed in accordance with contract schedules. |
• | Our investment portfolio balances at March 31, 2015 and December 31, 2014; |
• | Gross unrealized capital gains and losses by major security type; |
• | Debt securities with unrealized capital losses (including the amounts related to experience-rated and discontinued products); |
• | Our net realized capital gains and losses; and |
• | Our mortgage loan portfolio. |
(Millions) | 2015 | 2014 | |||||
Cash flows from operating activities | |||||||
Health Care and Group Insurance | $ | 1,556.2 | $ | 1,508.7 | |||
Large Case Pensions | (82.8 | ) | (86.5 | ) | |||
Net cash provided by operating activities | 1,473.4 | 1,422.2 | |||||
Cash flows from investing activities | |||||||
Health Care and Group Insurance | (92.3 | ) | (407.7 | ) | |||
Large Case Pensions | 114.1 | 153.9 | |||||
Net cash provided by (used for) investing activities | 21.8 | (253.8 | ) | ||||
Net cash used for financing activities | (999.8 | ) | (506.6 | ) | |||
Net increase in cash and cash equivalents | $ | 495.4 | $ | 661.8 |
Item 3. | Quantitative and Qualitative Disclosures About Market Risk |
Item 4. | Controls and Procedures |
Part II. | Other Information |
Item 1. | Legal Proceedings |
Item 1A. | Risk Factors |
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds |
Issuer Purchases of Equity Securities (1) | |||||||||||||
(Millions, except per share amounts) | Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs | |||||||||
January 1, 2015 - January 31, 2015 | 1.3 | $ | 91.61 | 1.3 | $ | 1,229.0 | |||||||
February 1, 2015 - February 28, 2015 | .5 | 94.03 | .5 | 1,209.4 | |||||||||
March 1, 2015 - March 31, 2015 | .3 | 103.99 | .3 | 1,182.7 | |||||||||
Total | 2.1 | $ | 93.69 | 2.1 | N/A | ||||||||
(1) | The remaining share repurchase authorization as of January 31, 2015 has been reduced for the entire $150.0 million paid in connection with an accelerated share repurchase program. The number of shares purchased under the accelerated share repurchase program is presented in January 2015 and February 2015, based upon when the shares were ultimately delivered to the Company. |
10 | Material contracts |
10.1 | Letter agreement dated December 17, 2012 between Aetna Life Insurance Company and Francis S. Soistman. * |
10.2 | Form of Aetna Inc. 2010 Stock Incentive Plan – Performance Stock Unit Terms of Award. * |
10.3 | Form of Aetna Inc. 2010 Stock Incentive Plan – Executive Restricted Stock Unit Terms of Award. * |
10.4 | Form of Aetna Inc. 2010 Stock Incentive Plan – Stock Appreciation Right Terms of Award. * |
11 | Statements re: computation of per share earnings |
11.1 | Computation of per share earnings is incorporated herein by reference to Note 3 of Condensed Notes to Consolidated Financial Statements, beginning on page 9 in this Form 10-Q. |
12 | Statements re: computation of ratios |
12.1 | Computation of ratio of earnings to fixed charges. |
15 | Letter re: unaudited interim financial information |
15.1 | Letter from KPMG LLP acknowledging awareness of the use of a report dated April 28, 2015 related to their review of interim financial information. |
31 | Rule 13a-14(a)/15d-14(a) Certifications |
31.1 | Certification. |
31.2 | Certification. |
32 | Section 1350 Certifications |
32.1 | Certification. |
32.2 | Certification. |
101 | XBRL Documents |
101.INS | XBRL Instance Document. |
101.SCH | XBRL Taxonomy Extension Schema. |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase. |
101.DEF | XBRL Taxonomy Extension Definition Linkbase. |
101.LAB | XBRL Taxonomy Extension Label Linkbase. |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase. |
Aetna Inc. | |
Registrant |
Date: | April 28, 2015 | By | /s/ Rajan Parmeswar |
Rajan Parmeswar | |||
Vice President, Controller and | |||
Chief Accounting Officer |
INDEX TO EXHIBITS | |||
Exhibit | Filing | ||
Number | Description | Method |
10 | Material contracts | ||
10.1 | Letter agreement dated December 17, 2012 between Aetna Life Insurance Company and Francis S. Soistman. * | Electronic | |
10.2 | Form of Aetna Inc. 2010 Stock Incentive Plan – Performance Stock Unit Terms of Award. * | Electronic | |
10.3 | Form of Aetna Inc. 2010 Stock Incentive Plan – Executive Restricted Stock Unit Terms of Award. * | Electronic | |
10.4 | Form of Aetna Inc. 2010 Stock Incentive Plan – Stock Appreciation Right Terms of Award. * | Electronic | |
12 | Statements re: computation of ratios | ||
12.1 | Computation of ratio of earnings to fixed charges. | Electronic | |
15 | Letter re: unaudited interim financial information | ||
15.1 | Letter from KPMG LLP acknowledging awareness of the use of a report dated April 28, 2015 related to their review of interim financial information. | Electronic | |
31 | Rule 13a-14(a)/15d-14(a) Certifications | ||
31.1 | Certification. | Electronic | |
31.2 | Certification. | Electronic | |
32 | Section 1350 Certifications | ||
32.1 | Certification. | Electronic | |
32.2 | Certification. | Electronic | |
101 | XBRL Documents | ||
101.INS | XBRL Instance Document. | Electronic | |
101.SCH | XBRL Taxonomy Extension Schema. | Electronic | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase. | Electronic | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase. | Electronic | |
101.LAB | XBRL Taxonomy Extension Label Linkbase. | Electronic | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase. | Electronic | |
By: | /s/ Alison Rogers-McCoy |
Alison Rogers-McCoy |
Accepted: | /s/ Francis S. Soistman | Date: | 12/20/12 | |
1. | I covenant and agree that so long as I am employed with the Company and for a period of twelve (12) months after my employment with the Company has been terminated for any reason, whether with or without cause and whether voluntarily or involuntarily, I will not directly or indirectly, (a) engage in the ownership (except less than 1% of the outstanding capital stock of any publicly traded company) of, (b) become an employee of, or (c) act as a consultant or contractor to, any competitor of the Company engaged in health care business ("Competitor"). For purposes of Paragraph 1 of this Agreement, "Competitor" shall mean the four companies (and their respective subsidiaries and affiliates) on a list provided by the Company to me (the “Specified Entities”). The initial list of Specified Entities shall be provided simultaneously with execution of this Agreement. The Specified Entities may be changed by the Company from time to time (but shall never be more than four) by delivering a new list to me, provided that any change in the list delivered to me within 90 days prior to or at any time after termination of my employment with the Company shall be null and void. Notwithstanding the foregoing, if my employment is involuntarily terminated by the Company, other than for cause, the length of this non-competition covenant shall not exceed the length of the period in which severance and/or salary continuation benefits are paid to me by the Company. The Company does not intend to enforce the restrictions in this paragraph to the extent (a) such enforcement would violate applicable law or (b) the restrictions are invalid or void under applicable law. |
2. | I covenant and agree that for a period of twenty-four (24) months after my employment with the Company has been terminated for any reason, whether with or without cause and whether voluntarily or involuntarily, I will not directly or indirectly (a) solicit or aid in the solicitation of any employee of the Company, (b) solicit or aid in the solicitation on behalf of a Competitor of any customer of the Company with whom I have been personally involved, either directly or indirectly, or (c) induce any health care supplier or provider, broker or agent of the Company to cease or curtail providing services to the Company. As used in this Agreement, for solicitation purposes only a “Competitor” is any company or organization that develops, administers, operates, offers or solicits offers regarding medical, pharmacy, dental, behavioral health, group life, long-term care and disability, medical management, networks, insurance or plans to employers, employees or individuals. The Company does not intend to enforce the restrictions in this paragraph to the extent (a) such enforcement would violate applicable law or (b) the restrictions are invalid or void under applicable law. |
3. | The Company agrees to provide me with access to the Company's trade secrets, confidential information, and proprietary materials which may include but are not limited to the following categories of information and materials: methods, procedures, computer programs, databases, customer lists and identities, provider lists and identities, employee lists and identities, processes, premium and other pricing information, research, payment rates, methodologies, contractual forms, and other information which is not publicly available generally and which has been developed or acquired by the Company with considerable effort and expense (“Confidential Information”). I covenant and agree to hold all of the foregoing trade secrets, Confidential Information and proprietary materials in the strictest confidence and shall not disclose, divulge or reveal the same to any person or entity during the term of my employment with the Company or at any time thereafter. |
4. | I understand that I am an at-will employee and that either I or the Company may terminate our employment relationship at any time, with or without cause or notice. Upon such termination, and prior to such termination upon request of the Company, I shall immediately return to the Company all Company property, documentation, trade secrets, Confidential Information and proprietary materials in my possession, custody or control, and shall return any copies thereof. After termination of my employment with the Company, I further agree to cooperate reasonably with all matters requested by the Company within the scope of my employment with the Company. |
5. | The purpose of this Agreement, among other things, is to protect the Company from unfair or inappropriate competition and to protect its trade secrets, Confidential Information and business relationships. I agree that if the scope of enforcement of this Agreement is ever disputed, a court or other competent trier of fact may modify and enforce it to the extent it believes is lawful and appropriate. |
6. | I acknowledge that all original works of authorship that are made by me (solely or jointly with others) within the scope of my employment and which are protectable by copyright are "works made for hire" as that term is defined in the United States Copyright Act (17 U.S.C., Section 101). I further acknowledge that, while employed by the Company, I may develop ideas, inventions, innovations, procedures, methods, know-how or other works which relate to the Company's current or are reasonably expected to relate to the Company’s future business that may be patentable. To the extent any such works may be patentable, I agree that the Company may file and prosecute any application for patents in my name and that I will, on request, assign to the Company (and take all such further steps as may be reasonably necessary to perfect the Company's sole and exclusive ownership of) any such application and any patents resulting therefrom. |
7. | I acknowledge that compliance with this Agreement is necessary to protect the business and good will of the Company and that any actual or prospective breach will cause injury or damage to the Company which may be irreparable and for which money damages may not be adequate. I therefore agree that if I breach or attempt to breach this Agreement, the Company shall be entitled to obtain temporary, preliminary and permanent equitable relief, without bond, to prevent irreparable harm or injury, and to money damages, together with any and all other remedies available under applicable law. I understand that I shall be liable to pay the Company's reasonable attorneys' fees and costs in any successful action to enforce this agreement. |
8. | Any controversy or claim arising out of or relating to this Agreement or the breach, termination, or validity thereof, except for temporary, preliminary, or permanent injunctive |
9. | This Agreement shall be construed in accordance with the laws of the State of Connecticut. I hereby irrevocably consent to the personal jurisdiction of the courts of the State of Connecticut, it being acknowledged that the Company maintains its headquarters in said location. |
10. | This Agreement (together with the list of Specified Entities referenced in Paragraph 1) constitutes the entire understanding and agreement between the parties with respect to the subject matter hereof, and no verbal or other statements, inducements or representations have been made or relied upon by any party. No modification or change to this Agreement shall be binding upon any party unless in writing executed by all parties. |
11. | I acknowledge that the Company is relying upon my foregoing commitments and obligations in revealing trade secrets and confidential information to me, in making any future annual |
Executed by: | Accepted by: |
FRANCIS S. SOISTMAN, JR., | AETNA INC. |
/s/ Francis S. Soistman, Jr. | By: | /s/ Alison Rogers-McCoy |
<name> (Signature) | Alison Rogers-McCoy | |
Francis S. Soistman, Jr. | 12/20/12 | |
(Printed Name) | (Date) | |
Head of Medicare | ||
(Title) | ||
12/20/12 | ||
(Date) |
(a) | “Affiliate" means an entity at least a majority of the total voting power of the then-outstanding voting securities of which is held, directly or indirectly, by the Company and/or one or more other Affiliates. |
(b) | "Board" means the Board of Directors of Aetna Inc. |
(i) | When any "person" as defined in Section 3(a)(9) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and as used in Sections 13(d) and 14(d) thereof, including a "group" as defined in Section 13(d) of the Exchange Act but excluding the Company and any Subsidiary thereof and any employee benefit plan sponsored or maintained by the Company or any Subsidiary (including any trustee of such plan acting as trustee), directly or indirectly, becomes the "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act, as amended from time to time), of securities of the Company representing 20 percent or more of the combined voting power of the Company's then outstanding securities; |
(ii) | When, during any period of 24 consecutive months, the individuals who, at the beginning of such period, constitute the Board (the "Incumbent Directors") cease for any reason other than death to constitute at least a majority thereof, provided that a director who was not a director at the beginning of such 24-month period shall be deemed to have satisfied such 24-month requirement (and be an Incumbent Director) if such director was elected by, or on the recommendation of or with the approval of, at least two-thirds of the directors who then qualified as Incumbent Directors either actually (because they were directors at the beginning of such 24-month period) or by prior operation of this paragraph (ii); or |
(iii) | The occurrence of a transaction requiring stockholder approval for the acquisition of the Company by an entity other than the Company or a Subsidiary through purchase of assets, or by merger, or otherwise. |
(d) | "Committee" means the Board's Committee on Compensation and Organization or any successor thereto. |
(e) | "Common Stock" means the Company's Common Shares, $.01 par value per share. |
(f) | "Company" means Aetna Inc. |
(g) | "Effective Date" means the date of grant of this award of Performance Stock Units. |
(h) | “Fair Market Value" means the closing price of the Common Stock as reported by the Consolidated Tape of the New York Stock Exchange Listed Shares on the date such value is to be determined, or, if no shares were traded on such date, on the next day on which the Common Stock is traded. |
(i) | “Fundamental Corporate Event” shall mean any stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares, warrants or rights offering to purchase Common Stock at a price substantially below fair market value, or similar event. |
(j) | "Grantee" means the person to whom this award has been granted. |
(k) | “Holding Company” means an entity that becomes a holding company for the Company or its businesses as a part of any reorganization, merger, consolidation or other transaction, provided that the outstanding shares of common stock of such entity and the combined voting power of the then outstanding voting securities of such entity entitled to vote generally in the election of directors is, immediately after such reorganization, merger, consolidation or other transaction, beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the voting stock outstanding immediately prior to such reorganization, merger, consolidation or other transaction in substantially the same proportions as their ownership, immediately prior to such reorganization, merger, consolidation or other transaction, of such outstanding voting stock. |
(l) | "Long Term Disability" means long-term disability as defined under the terms of the Company's applicable long-term disability plans or policies. |
(m) | “Net Shares” means the number of shares of Common Stock which will be deposited in a brokerage account in the Grantee’s name at the Company’s designated broker after shares have been withheld to satisfy applicable tax and withholding requirements upon vesting of the Performance Stock Units. |
(n) | “Performance Period” means the [ ] month performance period ending [date]. The Performance Period shall run from [date] to [date]. |
(o) | “Performance Stock Units” means the number of shares of Common Stock represented by the number of units awarded or such other amount as may result by operation of Article III of this Agreement. |
(p) | “Plan” means the Aetna Inc. 2010 Stock Incentive Plan. |
(q) | "Retirement" means the termination of employment of a Grantee from active service with the Company, any Subsidiary or Affiliate provided the Grantee’s age and completed years of service total 65 or more points at termination of employment. |
(r) | “Section 409A” means Section 409A of the Internal Revenue Code of 1986, as amended, and the regulation issued thereunder, as may be amended from time to time. |
(s) | “Shares of Stock” or “Stock” means the Common Stock. |
(t) | "Subsidiary" means an entity of which, at the time such subsidiary status is to be determined, at least 50% of the total combined voting power of all classes of stock of such entity is held by the Company and/or one or more other subsidiaries. |
(u) | "Successor" means the legal representative of the estate of a deceased Grantee or the person or persons who shall acquire the right to the Performance Stock Units by bequest or inheritance or by reason of the death of the Grantee. |
(v) | “Vest Date” means the last day of the Vesting Period and is the date on which this award of Performance Stock Units shall vest in accordance with the terms of this Agreement and in the Notice of Performance Stock Unit Grant, if at all. |
(w) | “Vesting Period” means the period beginning on the Effective Date and ending thirty-six months thereafter. |
(a) | Except as provided in (c) below, if, during the Vesting Period, Grantee shall cease to be employed by the Company, any Subsidiaries or Affiliates, for reason of death, Long-term Disability, Retirement or involuntary termination of employment by the Company, the portion of the Performance Stock Units that may vest on the Vest Date, if any, shall be calculated in accordance with the following formula: (i) the number of completed months employed during the Vesting period divided by the number of months in the Vesting Period; multiplied by (ii) the number of Performance Stock Units, that otherwise would have vested. For purposes of this calculation, a month is complete on the day in the month that corresponds to the Effective Date of the grant (e.g., February 12 to March 12). |
(b) | Except as provided in (a) above, any Performance Stock Unit not vested as of the date Grantee terminates employment shall be forfeited at the time of cessation of employment; provided, however, that if Grantee’s employment is terminated by the Company other than for cause and Grantee has not previously, or does not subsequently, vest to any portion of the Performance Stock Unit in accordance with its terms, then upon the forfeiture of the entire Performance Stock Unit, the Company will pay Grantee an amount equal to the value of a single share of Common Stock, whether or not the forfeited Performance Stock Unit related to more than a single share of Common Stock, calculated as of the cessation of employment, if requested by Grantee, within 30 days of such cessation of employment. |
(c) | No Performance Stock Unit will vest after the Company has terminated the employment of the Grantee for cause, unless the Committee, in its sole discretion, deems a payment to be warranted under the particular circumstances. In addition, the Performance Stock Units will not vest if Grantee has willfully engaged in gross misconduct or other serious impropriety which the Company determines is likely to be damaging or detrimental to the Company, any Subsidiary or Affiliate. |
(d) | Employment for purposes of determining the vesting rights of the Grantee and the expiration of the grant under this Article V shall mean continuous active full-time salaried employment with the Company, any Subsidiary or Affiliate, except that the period during which the Grantee is on vacation, sick leave, or other pre-approved leave of absence (provided there is no actual termination of employment), shall not interrupt the continuous employment of the Grantee. Employment shall also include service with Aetna Foundation, Inc. Notwithstanding any period during which Grantee receives salary continuation or severance shall not be considered as part of the continuous employment of the Grantee. |
(a) | As consideration for this grant of Performance Stock Units, without prior written consent of the Company: |
(i) | Grantee will not (except to the extent required by an order of a court having competent jurisdiction or under subpoena from an appropriate government agency) use or disclose to any third person, whether during or subsequent to Grantee’s employment, any trade secrets, confidential information and proprietary materials, which may include, but are not limited to, the following categories of information and materials: customer lists and identities; provider lists and identities; employee lists and identities; product development and related information; marketing plans and related information; sales plans and related information; premium or other pricing information; operating policies and manuals; research; payment rates; methodologies; procedures; contractual forms; business plans; financial records; computer programs; database; or other financial, commercial, business or technical information related to the Company, any Subsidiary or Affiliate unless such information has been previously disclosed to the public by the Company or has become public knowledge other than by a breach of this Agreement (“Confidential Information”); provided, however, that this limitation shall not apply to any such use or disclosure made while Grantee is employed by the Company, any Subsidiary or Affiliate if such disclosure occurred in connection with the performance of Grantee’s job as an employee of the Company, any Subsidiary or Affiliate; |
(ii) | Grantee will not, during and for a period of twelve (12) months following Grantee’s termination of employment, directly or indirectly, (x) engage in the ownership (except less than 1% of the outstanding capital stock of any publicly traded company) of or, (y) become an employee of, or (z) act as a consultant or contractor to, any competitor of the Company (“Competitor”) in any market in the United States where Company, Affiliate or Subsidiary does business. |
a. | For purposes of this paragraph “Competitor” shall mean any entity, organization, person or corporation that is involved in the same business as Company, Subsidiary or Affiliate, but in the case of (y) and (z), only to the extent such work, consulting or other activity on behalf of other entity, organization, person or corporation |
i. | is materially similar to the duties and/or functions that Grantee performed for the Company, Subsidiary or Affiliate in the last 12 months or involves duties and/or functions for Competitor about which Grantee has Confidential Information in the last 12 months. Notwithstanding |
1. | with respect to sales functions for the Company, Subsidiary or Affiliate that are regionally based or whose focus is geographically limited, the restriction shall only apply where such work, consulting or other activity on behalf of a Competitor overlaps in whole or in part the same geographic area in which the Grantee worked for Company, Subsidiary or Affiliate in the last 12 months; |
2. | with respect to corporate staff functions, the restriction shall only apply where Competitor is substantially engaged in the business of health insurance, managed health care, population health management, or related products or services. |
b. | Notwithstanding, if Grantee’s employment is terminated by the Company, Subsidiary or Affiliate other than for cause, the length of the noncompetition covenant in this paragraph shall not exceed the length of the severance and/or salary continuation benefits paid by the Company, Subsidiary or Affiliate to Grantee. |
c. | Grantee acknowledges and agrees that these restrictions: |
i. | are necessary to protect the Confidential Information and goodwill of the Company, Subsidiary or Affiliate; |
ii. | are appropriately tailored and limited in time and geographic scope to do so; and |
iii. | do not impair or limit the Grantee’s ability to earn a living. |
(iii) | Grantee will not, during and for a period of 24 months following Grantee’s termination of Employment, directly or indirectly induce or attempt to induce any employee of the Company, any Subsidiary or Affiliate to be employed or perform services elsewhere; |
(iv) | Grantee will not, during and for a period of 24 months following Grantee's termination of Employment, directly or indirectly, induce or attempt to induce any agent or agency, broker, supplier or health care provider of the Company, any Subsidiary or Affiliate to cease or curtail providing services to the Company, any Subsidiary or Affiliate; and |
(v) | Grantee will not, during and for a period of 24 months following Grantee’s termination of Employment, directly or indirectly solicit or attempt to solicit the trade of any individual or entity which, at the time of such solicitation, is a customer of the Company, any Subsidiary or Affiliate, or which the Company, any Subsidiary or Affiliate is undertaking reasonable steps to procure as a customer at the time of or immediately preceding termination of Employment; provided, however, that this limitation shall only apply to any product or service which is in competition with a product or service of the Company, any Subsidiary or Affiliate and shall apply only with respect to a customer or prospective customer with whom the Grantee has been directly or indirectly involved. |
(vi) | Grantee will not, during and for a period of 24 months following Grantee’s termination of Employment, for himself or herself or on behalf of or in cooperation with any other person or entity, consult with or in any manner provide advice to, any individual or entity which is a customer of the Company or any Subsidiary or Affiliate of the Company, provided, however, that this limitation shall apply only to consultation or advice relating to any product or service of the Company, or any Subsidiary or Affiliate, or which is in competition with any product or service of the Company, or any Subsidiary or Affiliate, and shall apply only with respect to a customer or prospective customer with whom the Grantee has been directly or indirectly involved, or about which Grantee has Confidential Information. |
(vii) | Following the termination of Grantee’s Employment, Grantee shall provide assistance to and shall cooperate with the Company, any Subsidiary or Affiliate, upon its reasonable request and without additional compensation, with respect to matters within the scope of Grantee’s duties and responsibilities during Employment, provided that any reasonable out-of-pocket expenses Grantee incurs in connection with any assistance Grantee has been requested to provide under this provision for items including, but not limited to, transportation, meals, lodging and telephone, shall be reimbursed by the Company. The Company agrees and acknowledges that it shall, to the maximum extent possible under the then prevailing circumstances, coordinate, or cause a Subsidiary or Affiliate to coordinate, any such request with Grantee’s other commitments and responsibilities to minimize the degree to which such request interferes with such commitments and responsibilities; and |
(viii) | Grantee shall promptly notify the Company’s General Counsel if Grantee is contacted by a regulatory or self-regulatory agency with respect to matters pertaining to the Company or by an attorney or other individual who informs the Grantee that he/she has filed, intends to file, or is considering filing a claim or complaint against the Company. |
(ix) | Grantee acknowledges that all original works of authorship that are created by Grantee (solely or jointly with others) within the scope of Grantee’s employment and relating in any way to the business or contemplated business, products, activities, research or development of the Company, any Subsidiary or Affiliate, or resulting from any work performed by the Grantee for the Company, any Subsidiary or Affiliate (in each case, regardless of when or where the work product is prepared or whose equipment or other resources is used in preparing the same) which are protectable by copyright are “works made for hire” as that term is defined in the United States Copyright Act (17 U.S.C., Section 101). To the extent that the foregoing does not apply, the Grantee hereby irrevocably assigns to the Company, and its successors and assigns, for no additional consideration, the Grantee’s entire right, title and interest in and to all such works of authorship. Grantee further acknowledges that while employed by the Company, any Subsidiary or Affiliate, Grantee may develop ideas, inventions, discoveries, innovations, procedures, methods, know-how or other works which relate to the Company’s current or are reasonably expected to relate to the Company’s future business (in each case, regardless of when or where the work product is prepared or whose equipment or other resources is used in preparing the same) that may be patentable or subject to trade secret protection. Grantee agrees that all such works of authorship, ideas, inventions, discoveries, innovations, procedures, methods, know-how and other works shall belong exclusively to the Company, and the Grantee hereby assigns all right, title, and interest therein to the Company. |
(b) | If any provision of Article VI (a) is determined by a court of competent jurisdiction not to be enforceable in the manner set forth herein, the Company and Grantee agree that it is the intention of the parties that such provision should be enforceable to the maximum extent possible under applicable law and that such court shall reform such provision to make it enforceable in accordance with the intent of the parties. |
(c) | Grantee acknowledges that a material part of the inducement for the Company to grant the Performance Stock Units is Grantee’s covenants set forth in Article VI (a) and that the covenants and obligations of Grantee with respect to nondisclosure, non-solicitation and cooperation relate to special, unique and extraordinary matters and that a violation of any of the terms of such covenants and obligations will cause the Company irreparable injury for which adequate remedies are not available at law. Therefore, Grantee agrees that, if Grantee shall breach any of those covenants or obligations, Grantee shall not be entitled to vest in the Performance Stock or be entitled to retain any income therefrom and the Company shall be entitled to an injunction, restraining order or such other equitable relief (without the requirement to post bond) restraining Grantee from committing any violation of the covenants and obligations contained in Article VI. The Company also shall be entitled to recover any attorneys’ fees, costs, and expenses it incurs in connection with any judicial proceeding arising out of Grantee’s breach of this Agreement. The remedies in the preceding sentences are cumulative and are in addition to any other rights and remedies the Company may have at law or in equity as a court or arbitrator shall reasonably determine. |
(d) | The Restrictive Covenants set forth in this Article VI shall supplement and do not supersede the restrictions agreed to by Grantee in any other agreement or contract. |
(e) | Employment Dispute Arbitration Program - Mandatory Binding Arbitration of Employment Disputes. |
(i) | Except as otherwise specified in this Agreement, the Grantee and the Company agree that all employment-related legal disputes between them will be submitted to and resolved by binding arbitration, and neither the Grantee nor the Company will file or participate as an individual party or member of a class in a lawsuit in any court against the other with respect to such matters. This shall apply to claims brought on or after the date the Grantee accepts this Agreement, even if the facts and circumstances relating to the claim occurred prior to that date and regardless of whether the Grantee or the Company previously filed a complaint/charge with a government agency concerning the claim. |
(ii) | THE GRANTEE UNDERSTANDS THAT THE ARBITRATION PROVISIONS OF THIS AGREEMENT AFFECT THE LEGAL RIGHTS OF THE GRANTEE AND THE COMPANY AND ACKNOWLEDGES THAT THE GRANTEE HAS BEEN ADVISED TO, AND HAS BEEN GIVEN THE OPPORTUNITY TO, OBTAIN LEGAL ADVICE BEFORE SIGNING THIS AGREEMENT. |
(iii) | Article VI (e) of this Agreement does not apply to workers’ compensation claims, unemployment compensation claims, and claims under the Employee Retirement Income Security Act of 1974 (“ERISA”) for employee benefits. A dispute as to whether Article VI (e) of this Agreement applies must be submitted to the binding arbitration process set forth in this Agreement. |
(iv) | The Grantee and/or the Company may seek emergency or temporary injunctive relief from a court (including with respect to claims arising out of Article VI (a) in accordance with applicable law). However, except as provided in Article VI (c) of this Agreement, after the court has issued a ruling concerning the emergency or temporary injunctive relief, the Grantee and the Company shall be required to submit the dispute to binding arbitration pursuant to this Agreement. |
(v) | Unless otherwise agreed, the arbitration will be administered by the American Arbitration Association (the “AAA”) and will be conducted pursuant to the AAA’s Employment Arbitration Rules and Mediation Procedures (the “Rules”), as modified in this Agreement, in effect at the time the request for arbitration is filed. The AAA’s Rules are available on the AAA’s website at www.adr.org. THE GRANTEE ACKNOWLEDGES THAT THE COMPANY HAS ENCOURAGED THE GRANTEE TO READ THESE RULES PROMPTLY AND CAREFULLY AND THAT THE GRANTEE HAS BEEN AFFORDED SUFFICIENT OPPORTUNITY TO DO SO. |
(vi) | If the Company initiates a request for arbitration, the Company will pay all of the administrative fees and costs charged by the AAA, including the arbitrator’s compensation and charges for hearing room rentals, etc. If the Grantee initiates a request for arbitration or submits a counterclaim to the Company’s request for arbitration, the Grantee shall be required to contribute One Hundred Dollars ($100.00) to those administrative fees and costs, payable to the AAA at the time the Grantee's request for arbitration or counterclaim is submitted. The Company may increase the contribution amount in the future without amending this Agreement, but not to exceed the maximum permitted under the AAA rules then in effect. In all cases, the Grantee and the Company shall be responsible for payment of any fees assessed by the arbitrator as a result of that party’s delay, request for postponement, failure to comply with the arbitrator’s rulings and for other similar reasons. |
(vii) | The Grantee and the Company may choose to be represented by legal counsel in the arbitration process and shall be responsible for their own legal fees, expenses and costs. However, the arbitrator shall have the same authority as a court to order the Grantee or the Company to pay some or all of the other’s legal fees, expenses and costs, in accordance with applicable law. |
(viii) | Unless otherwise agreed, there shall be a single arbitrator, selected by the Grantee and the Company from a list of qualified neutrals furnished by the AAA. If the Grantee and the Company cannot agree on an arbitrator, one will be selected by the AAA. |
(ix) | Unless otherwise agreed, the arbitration hearing will take place in the city where the Grantee works or last worked for the Company. If the Grantee and the Company disagree as to the proper locale, the AAA will decide. |
(x) | The Grantee and the Company shall be entitled to conduct limited pre-hearing discovery. Each may take the deposition of one person and anyone designated by the other as an expert witness. The party taking the deposition shall be responsible for all associated costs, such as the cost of a |
(xi) | The arbitrator shall apply the same substantive law that would apply if the matter were heard by a court and shall have the authority to order the same remedies (but no others) as would be available in a court proceeding. The time limits for requesting arbitration or submitting a counterclaim and the administrative prerequisites for filing an arbitration claim or counterclaim are the same as they would be in a court proceeding. The arbitrator shall consider and decide any dispositive motions (motions seeking a decision on some or all of the claims or counterclaims without an arbitration hearing) filed by any party. |
(xii) | All proceedings, including the arbitration hearing and decision, are private and confidential, unless otherwise required by law. Arbitration decisions may not be published or publicized without the consent of both the Grantee and the Company. |
(xiv) | The arbitrator’s decision is final and binding on the Grantee and the Company. After the arbitrator’s decision is issued, the Grantee or the Company may obtain an order of judgment from a court and may obtain a court order enforcing the decision. The arbitrator’s decision may be appealed to the courts only under the limited circumstances provided by law. |
(xv) | If the Grantee previously signed an agreement, including but not limited to an employment agreement, containing arbitration provisions, those provisions are superseded by the arbitration provisions of this Agreement. |
(xvi) | If any provision of Article VI (e) is found to be void or otherwise unenforceable, in whole or in part, this shall not affect the validity of the remainder of Article VI (e) and the remainder of the Agreement. All other provisions shall remain in full force and effect. |
(f) | Except as provided in connection with mandatory binding arbitration of employment disputes, Grantee hereby submits to the exclusive jurisdiction of the courts of the State of Connecticut and the United States District Court for the District of Connecticut with respect to any action relating to this Agreement, and agrees that (i) the sole and exclusive appropriate venue for any suit or proceeding relating to this Agreement shall be in such court, and (ii) hereby waives any and all objections and defenses based on forum, venue or personal or subject matter jurisdiction as they may relate to a suit or proceeding brought before such court in accordance with the Agreement. |
(a) | Nothing in this Agreement shall interfere with or limit in any way the right of the Company, any Subsidiary or Affiliate to terminate the Grantee’s employment at any time. Neither the execution and delivery hereof nor the granting of the Award shall constitute or be evidence of any agreement or understanding, express or implied, on the part of the Company or any of its Subsidiaries to employ or continue the employment of the Grantee for any period. |
(b) | Until the Performance Stock Units have become vested, Grantee shall not have any rights as a stockholder (including the right to payment of dividends) by virtue of this grant of Performance Stock Units. |
(c) | During the Vesting Period, the Performance Stock Units shall be nontransferable and non-assignable except by will or the laws of descent and distribution. |
(d) | The award, when vested, will be settled on a net basis. Prior to issuing any Common Shares, the Company will withhold an amount sufficient to satisfy federal, state, local, social security and Medicare withholding tax requirements relating to award. Any social security calculation or other adjustments discovered after net share payment will be settled in cash, not in Shares of Common Stock. Vesting will result in taxable compensation reportable on the Grantee’s W-2 in year of vesting. |
(e) | The Company may from time to time adopt stock ownership requirements applicable to Grantees who are senior managers of the Company. In connection with and for the purpose of implementing those ownership requirements, the Company may adopt certain restrictions on the ability of a Grantee to sell shares issued under this Agreement when such ownership requirements have not been satisfied. Any such restriction on sale will be communicated generally to affected Grantees and the restriction may be modified by the Company from time to time, at its discretion. Neither the Company nor its Board of Directors shall have any obligation or liability to a Grantee in connection with any such restriction. |
(f) | This Performance Stock Unit is an unfunded obligation of the Company and nothing in this Agreement shall be construed to create any claim against particular assets or require the Company to segregate or otherwise set aside any assets or create any fund to meet its obligations hereunder. |
(g) | Anything herein to the contrary notwithstanding, a Grantee whose Performance Stock Units have been forfeited as a result of termination of employment due to U.S. Military Service and who is later re-employed (in a full-time active status) after discharge within the time period set in 38 U.S.C. Section 4312 will be eligible to have the forfeited Performance Stock Units reinstated as follows: (i) if such Grantee is re-employed during the Vesting Period, all forfeited Performance Stock Units shall be reinstated; or (ii) if such Grantee is re-employed after the Vesting Period, a cash payment will be made to the Grantee, minus applicable taxes, for the value of the forfeited Performance Stock Units on the Vest Date pursuant to procedures established by the Company for this purpose. |
(h) | It is the intention of the Company and Grantee that this Agreement not result in unfavorable tax consequences to Grantee under Section 409A and the Agreement shall be interpreted as to so comply. Notwithstanding anything to the contrary herein, the Company and Grantee agree to the provisions set forth below in order to comply with the requirements of Section 409A. |
(i) | If Grantee is a “specified employee” (within the meaning of Section 409A) with respect to the Company, any non-qualified deferred compensation otherwise payable to or in respect of Grantee in connection with Grantee’s termination of employment shall be delayed until the earliest date upon which such amounts may be paid without being subject to taxation under Section 409A. Any amount, the payment or benefit of which is delayed by application of the preceding sentence, shall be paid as soon as possible following the expiration of such period. |
(ii) | Unless deferred pursuant to this agreement, all payments shall be paid to Grantee, to the extent earned, in no event later than the last day of the “applicable 2 ½ month period,” as such term is defined in Treasury Regulation Section 1.409A-1(b)(4)(i)(A) with respect to such payment’s treatment as a “short-term deferral” for purposes of Section 409A. |
(iii) | The Company and Grantee agree to cooperate in good faith in an effort to comply with Section 409A. Under no circumstances shall the Company be responsible for any taxes, penalties, interest or other losses or expenses incurred by the Grantee due to any failure to comply with Section 409A. |
(i) | This Agreement is subject to the 2010 Stock Incentive Plan heretofore adopted by the Company and approved by its shareholders. The terms and provisions of the Plan (including any subsequent amendments thereto) are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail. |
(j) | At such times and upon such terms and conditions as the Company shall determine, the Company may permit eligible Grantees to elect to defer the distribution of an Award otherwise payable to the Grantee under this Agreement until termination of the Grantee’s Employment or such other date Company shall permit. |
(k) | This Agreement is made under and shall be governed by and construed in accordance with the laws of the State of Connecticut, without giving effect to its choice of law provisions. |
(a) | “Affiliate" means an entity at least a majority of the total voting power of the then-outstanding voting securities of which is held, directly or indirectly, by the Company and/or one or more other Affiliates. |
(b) | "Board" means the Board of Directors of Aetna Inc. |
(i) | When any "person" as defined in Section 3(a)(9) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and as used in Sections 13(d) and 14(d) thereof, including a "group" as defined in Section 13(d) of the Exchange Act but excluding the Company and any Subsidiary thereof and any employee benefit plan sponsored or maintained by the Company or any Subsidiary (including any trustee of such plan acting as trustee), directly or indirectly, becomes the "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act, as amended from time to time), of securities of the Company representing 20 percent or more of the combined voting power of the Company's then outstanding securities; |
(ii) | When, during any period of 24 consecutive months, the individuals who, at the beginning of such period, constitute the Board (the "Incumbent Directors") cease for any reason other than death to constitute at least a majority thereof, provided that a director who was not a director at the beginning of such 24-month period shall be deemed to have satisfied such 24-month requirement (and be an Incumbent Director) if such director was elected by, or on the recommendation of or with the approval of, at least two-thirds of the directors who then qualified as Incumbent Directors either actually (because they were directors at the beginning of such 24-month period) or by prior operation of this paragraph (ii); or |
(iii) | The occurrence of a transaction requiring stockholder approval for the acquisition of the Company by an entity other than the Company or a Subsidiary through purchase of assets, or by merger, or otherwise. |
(d) | "Committee" means the Board's Committee on Compensation and Organization or any successor thereto. |
(e) | "Common Stock" means the Company's Common Shares, $.01 par value per share. |
(f) | "Company" means Aetna Inc. |
(g) | "Effective Date" means the date of grant of this award of Restricted Stock Units. |
(h) | “Fair Market Value" means the closing price of the Common Stock as reported by the Consolidated Tape of the New York Stock Exchange Listed Shares on the date such value is to be determined, or, if no shares were traded on such date, on the next day on which the Common Stock is traded. |
(i) | “Fundamental Corporate Event” shall mean any stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares, warrants or rights offering to purchase Common Stock at a price substantially below fair market value, or similar event. |
(j) | "Grantee" means the person to whom this award has been granted. |
(k) | “Holding Company” means an entity that becomes a holding company for the Company or its businesses as a part of any reorganization, merger, consolidation or other transaction, provided that the outstanding shares of common stock of such entity and the combined voting power of the then outstanding voting securities of such entity entitled to vote generally in the election of directors is, immediately after such reorganization, merger, consolidation or other transaction, beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the voting stock outstanding immediately prior to such reorganization, merger, consolidation or other transaction in substantially the same proportions as their ownership, immediately prior to such reorganization, merger, consolidation or other transaction, of such outstanding voting stock. |
(l) | "Long Term Disability" means long-term disability as defined under the terms of the Company's applicable long-term disability plans or policies. |
(m) | “Net Shares” means the number of shares of Common Stock which will be deposited in a brokerage account in the Grantee’s name at the Company’s designated broker after shares have been withheld to satisfy applicable tax and withholding requirements upon vesting of the Restricted Stock Units. |
(n) | “Plan” means the Aetna Inc. 2010 Stock Incentive Plan. |
(o) | “Restricted Period” means the period during which this award of Restricted Stock Units is not vested. |
(p) | “Restricted Stock Units” means the number of shares of Common Stock represented by the number of units awarded or such other amount as may result by operation of Article III of this Agreement. |
(q) | "Retirement" means the termination of employment of a Grantee from active service with the Company, any Subsidiary or Affiliate provided the Grantee’s age and completed years of service total 65 or more points at termination of employment. |
(r) | “Section 409A” means Section 409A of the Internal Revenue Code of 1986, as amended, and the regulation issued thereunder, as may be amended from time to time. |
(s) | “Shares of Stock” or “Stock” means the Common Stock. |
(t) | "Subsidiary" means an entity of which, at the time such subsidiary status is to be determined, at least 50% of the total combined voting power of all classes of stock of such entity is held by the Company and/or one or more other subsidiaries. |
(u) | "Successor" means the legal representative of the estate of a deceased Grantee or the person or persons who shall acquire the right to the Restricted Stock Units by bequest or inheritance or by reason of the death of the Grantee. |
(v) | “Vest Date” means the date on which this award of Restricted Stock Units shall vest in accordance with the terms of this Agreement and as set forth on the website of the designated broker and in the Notice of Restricted Stock Unit Grant, if applicable. |
(a) | Except as provided in (f) below, if the Grantee shall die during the Restricted Period, the unvested Restricted Stock Units shall become immediately vested and Net Shares, if any, will be deposited with the Company’s designated broker in a brokerage account established in Grantee’s name. |
(b) | Except as provided in (f) below, if the Grantee shall begin to receive Long Term Disability benefits during the Restricted Period, the unvested Restricted Stock Units shall continue to vest and Net Shares, if any, will be deposited with the Company’s designated broker in a brokerage account established in Grantee’s name on the scheduled Vest Date(s) under Article II. |
(c) | Except as provided in (f) below, if, during the restricted period, Grantee shall cease to be employed by the Company, any Subsidiaries or Affiliates during the Restricted Period, for reason of Retirement or involuntary termination of employment by the Company, a portion of the Restricted Stock Units shall vest in accordance with the following formula: (i) the number of completed months employed after the Effective Date divided by the number of full months in the restricted period; multiplied by (ii) number of Restricted Stock Units, minus any vested Restricted Stock Units. For purposes of this calculation, a month is complete on the day in the following month that corresponds to the Effective Date (e.g., February 13 to March 13). Net shares, if any, will be deposited with the Company’s designated broker in a brokerage account established in Grantee’s name on the next scheduled Vest Date under Article II and, applicable taxes and withholding will be applied based on the Fair Market Value on that date. |
(d) | Except as provided in (e) and (f) below, if the Grantee shall, for a reason other than death, Long-Term Disability, Retirement or involuntary termination of employment by the Company, cease to be employed by the Company, any Subsidiaries or Affiliates during the Restricted Period, any unvested Restricted Stock Units shall be forfeited at the time of cessation of employment. |
(e) | Except as provided in (a) or (b) or (c) above, any Restricted Stock Unit not vested as of the date Grantee terminates employment shall be forfeited at the time of cessation of employment; provided, however, that if Grantee’s employment is terminated by the Company other than for cause and Grantee has not previously, or does not subsequently, vest to any portion of the Restricted Stock Unit in accordance with its terms, then upon the forfeiture of the entire Restricted Stock Unit, the Company will pay Grantee an amount equal to the value of a single share of Common Stock, whether or not the forfeited Restricted Stock Unit related to more than a single share of Common Stock, calculated as of the cessation of employment, if requested by Grantee, within 30 days of such cessation of employment. |
(f) | No Restricted Stock Unit will vest after the Company has terminated the employment of the Grantee for cause, unless the Committee, in its sole discretion, deems a payment to be warranted under the particular circumstances. In addition, the Restricted Stock Units will not vest if Grantee has willfully engaged in gross misconduct or other serious impropriety which the Company determines is likely to be damaging or detrimental to the Company, any Subsidiary or Affiliate. |
(g) | Employment for purposes of determining the vesting rights of the Grantee and the expiration of the grant under this Article V shall mean continuous full-time salaried employment with the Company, any Subsidiary or an Affiliate, except that the period during which the Grantee is on vacation, sick leave, or other pre-approved leave of absence (provided there is no actual termination of employment), or in receipt of salary continuation or severance pay shall not interrupt the continuous employment of the Grantee. Employment shall also include service with Aetna Foundation, Inc. |
(a) | As consideration for this grant of Restricted Stock Units, without prior written consent of the Company: |
(i) | Grantee will not (except to the extent required by an order of a court having competent jurisdiction or under subpoena from an appropriate government agency) use or disclose to any third person, whether during or subsequent to Grantee’s employment, any trade secrets, confidential information and proprietary materials, which may include, but are not limited to, the following categories of information and materials: customer lists and identities; provider lists and identities; employee lists and identities; product development and related information; marketing plans and related information; sales plans and related information; premium or other pricing information; operating policies and manuals; research; payment rates; methodologies; procedures; contractual forms; business plans; financial records; computer programs; database; or other financial, commercial, business or technical information related to the Company, any Subsidiary or Affiliate unless such information has been previously disclosed to the public by the Company or has become public knowledge other than by a breach of this Agreement (“Confidential Information”); provided, however, that this limitation shall not apply to any such use or disclosure made while Grantee is |
(ii) | Grantee will not, during and for a period of twelve (12) months following Grantee’s termination of employment, directly or indirectly, (x) engage in the ownership (except less than 1% of the outstanding capital stock of any publicly traded company) of or, (y) become an employee of, or (z) act as a consultant or contractor to, any competitor of the Company (“Competitor”) in any market in the United States where Company, Affiliate or Subsidiary does business. |
a. | For purposes of this paragraph “Competitor” shall mean any entity, organization, person or corporation that is involved in the same business as Company, Subsidiary or Affiliate, but in the case of (y) and (z), only to the extent such work, consulting or other activity on behalf of other entity, organization, person or corporation |
i. | is materially similar to the duties and/or functions that Grantee performed for the Company, Subsidiary or Affiliate in the last 12 months or involves duties and/or functions for Competitor about which Grantee has Confidential Information in the last 12 months. Notwithstanding |
1. | with respect to sales functions for the Company, Subsidiary or Affiliate that are regionally based or whose focus is geographically limited, the restriction shall only apply where such work, consulting or other activity on behalf of a Competitor overlaps in whole or in part the same geographic area in which the Grantee worked for Company, Subsidiary or Affiliate in the last 12 months; |
2. | with respect to corporate staff functions, the restriction shall only apply where Competitor is substantially engaged in the business of health insurance, managed health care, population health management, or related products or services. |
b. | Notwithstanding, if Grantee’s employment is terminated by the Company, Subsidiary or Affiliate other than for cause, the length of the noncompetition covenant in this paragraph shall not exceed the length of the severance and/or salary continuation benefits paid by the Company, Subsidiary or Affiliate to Grantee. |
c. | Grantee acknowledges and agrees that these restrictions: |
i. | are necessary to protect the Confidential Information and goodwill of the Company, Subsidiary or Affiliate; |
ii. | are appropriately tailored and limited in time and geographic scope to do so; and |
iii. | do not impair or limit the Grantee’s ability to earn a living. |
(iii) | Grantee will not, during and for a period of 24 months following Grantee’s termination of Employment, directly or indirectly induce or attempt to induce any employee of the Company, any Subsidiary or Affiliate to be employed or perform services elsewhere; |
(iv) | Grantee will not, during and for a period of 24 months following Grantee's termination of Employment, directly or indirectly, induce or attempt to induce any agent or agency, broker, supplier or health care provider of the Company, any Subsidiary or Affiliate to cease or curtail providing services to the Company, any Subsidiary or Affiliate; and |
(v) | Grantee will not, during and for a period of 24 months following Grantee’s termination of Employment, directly or indirectly solicit or attempt to solicit the trade of any individual or entity which, at the time of such solicitation, is a customer of the Company, any Subsidiary or Affiliate, or which the Company, any Subsidiary or Affiliate is undertaking reasonable steps to procure as a customer at the time of or immediately preceding termination of Employment; provided, however, that this limitation shall only apply to any product or service which is in competition with a product or service of the Company, any Subsidiary or Affiliate and shall apply only with respect to a customer or prospective customer with whom the Grantee has been directly or indirectly involved. |
(vi) | Grantee will not, during and for a period of 24 months following Grantee’s termination of Employment, for himself or herself or on behalf of or in cooperation with any other person or entity, consult with or in any manner provide advice to, any individual or entity which is a customer of the Company or any Subsidiary or Affiliate of the Company, provided, however, that this limitation shall apply only to consultation or advice relating to any product or service of the Company, or any Subsidiary or Affiliate, or which is in competition with any product or service of the Company, or any Subsidiary or Affiliate, and shall apply only with respect to a customer or prospective customer with whom the Grantee has been directly or indirectly involved, or about which Grantee has Confidential Information |
(vii) | Following the termination of Grantee’s Employment, Grantee shall provide assistance to and shall cooperate with the Company, any Subsidiary or Affiliate, upon its reasonable request and without additional compensation, with respect to matters within the scope of Grantee’s duties and responsibilities during Employment, provided that any reasonable out-of-pocket expenses Grantee incurs in connection with any assistance Grantee has been requested to provide under this provision for items including, but not limited to, transportation, meals, lodging and telephone, shall be reimbursed by the Company. The Company agrees and acknowledges that it shall, to the maximum extent possible under the then prevailing circumstances, coordinate, or cause a Subsidiary or Affiliate to coordinate, any such request with Grantee’s other commitments and responsibilities to minimize the degree to which such request interferes with such commitments and responsibilities; and |
(viii) | Grantee shall promptly notify the Company’s General Counsel if Grantee is contacted by a regulatory or self-regulatory agency with respect to matters pertaining to the Company or by an attorney or other individual who informs the Grantee that he/she has filed, intends to file, or is considering filing a claim or complaint against the Company. |
(ix) | Grantee acknowledges that all original works of authorship that are created by Grantee (solely or jointly with others) within the scope of Grantee’s employment and relating in any way to the business or contemplated business, products, activities, research or development of the Company, any Subsidiary or Affiliate, or resulting from any work performed by the Grantee for the Company, any Subsidiary or Affiliate (in each case, regardless of when or where the work product is prepared or whose equipment or other resources is used in preparing the same) which are protectable by copyright are “works made for hire” as that term is defined in the United States Copyright Act (17 U.S.C., Section 101). To the extent that the foregoing does not apply, the Grantee hereby irrevocably assigns to the Company, and its successors and assigns, for no additional consideration, the Grantee’s entire right, title and interest in and to all such works of authorship. Grantee further acknowledges that while employed by the Company, any Subsidiary or Affiliate, Grantee may develop ideas, inventions, discoveries, innovations, procedures, methods, know-how or other works which relate to the Company’s current or are reasonably expected to relate to the Company’s future business (in each case, regardless of when or where the work product is prepared or whose equipment or other resources is used in preparing the same) that may be patentable or subject to trade secret protection. Grantee agrees that all such works of authorship, ideas, inventions, discoveries, innovations, procedures, methods, know-how and other works shall belong exclusively to the Company, and the Grantee hereby assigns all right, title, and interest therein to the Company. |
(b) | If any provision of Article VI (a) is determined by a court of competent jurisdiction not to be enforceable in the manner set forth herein, the Company and Grantee agree that it is the intention of the parties that such provision should be enforceable to the maximum extent possible under applicable law and that such court shall reform such provision to make it enforceable in accordance with the intent of the parties. |
(c) | Grantee acknowledges that a material part of the inducement for the Company to grant the Restricted Stock Units is Grantee’s covenants set forth in Article VI (a) and that the covenants and obligations of Grantee with respect to nondisclosure, non-solicitation and cooperation relate to special, unique and extraordinary matters and that a violation of any of the terms of such covenants and obligations will cause the Company irreparable injury for which adequate remedies are not available at law. Therefore, Grantee agrees that, if Grantee shall breach any of those covenants or obligations, Grantee shall not be entitled to vest in the Restricted Stock or be entitled to retain any income therefrom and the Company shall be entitled to an injunction, restraining order or such other equitable relief (without the requirement to post bond) restraining Grantee from committing any violation of the covenants and obligations contained in Article VI. The Company also shall be entitled to recover any attorneys’ fees, costs, and expenses it incurs in connection with any judicial proceeding arising out of Grantee’s breach of this Agreement. The remedies in the preceding sentences are cumulative and are in addition to any other rights and remedies the Company may have at law or in equity as a court or arbitrator shall reasonably determine. |
(d) | The Restrictive Covenants set forth in this Article VI shall supplement and do not supersede the restrictions agreed to by Grantee in any other agreement or contract. |
(e) | Employment Dispute Arbitration Program - Mandatory Binding Arbitration of Employment Disputes. |
(i) | Except as otherwise specified in this Agreement, the Grantee and the Company agree that all employment-related legal disputes between them will be submitted to and resolved by binding arbitration, and neither the Grantee nor the Company will file or participate as an individual party or member of a class in a lawsuit in any court against the other with respect to such matters. This shall apply to claims brought on or after the date the Grantee accepts this Agreement, even if the facts and circumstances relating to the claim occurred prior to that date and regardless of whether the Grantee or the Company previously filed a complaint/charge with a government agency concerning the claim. |
(ii) | THE GRANTEE UNDERSTANDS THAT THE ARBITRATION PROVISIONS OF THIS AGREEMENT AFFECT THE LEGAL RIGHTS OF THE GRANTEE AND THE COMPANY AND ACKNOWLEDGES THAT THE GRANTEE HAS BEEN ADVISED TO, AND HAS BEEN GIVEN THE OPPORTUNITY TO, OBTAIN LEGAL ADVICE BEFORE SIGNING THIS AGREEMENT. |
(iii) | Article VI (e) of this Agreement does not apply to workers’ compensation claims, unemployment compensation claims, and claims under the Employee Retirement Income Security Act of 1974 (“ERISA”) for employee benefits. A dispute as to whether Article VI (e) of this Agreement applies must be submitted to the binding arbitration process set forth in this Agreement. |
(iv) | The Grantee and/or the Company may seek emergency or temporary injunctive relief from a court (including with respect to claims arising out of Article VI (a) in accordance with applicable law). However, except as provided in Article VI (c) of this Agreement, after the court has issued a ruling concerning the emergency or temporary injunctive relief, the Grantee and the Company shall be required to submit the dispute to binding arbitration pursuant to this Agreement. |
(v) | Unless otherwise agreed, the arbitration will be administered by the American Arbitration Association (the “AAA”) and will be conducted pursuant to the AAA’s Employment Arbitration Rules and Mediation Procedures (the “Rules”), as modified in this Agreement, in effect at the time the request for arbitration is filed. The AAA’s Rules are available on the AAA’s website at www.adr.org. THE GRANTEE ACKNOWLEDGES THAT THE COMPANY HAS ENCOURAGED THE GRANTEE TO READ THESE RULES PROMPTLY AND CAREFULLY AND THAT THE GRANTEE HAS BEEN AFFORDED SUFFICIENT OPPORTUNITY TO DO SO. |
(vi) | If the Company initiates a request for arbitration, the Company will pay all of the administrative fees and costs charged by the AAA, including the arbitrator’s compensation and charges for hearing room rentals, etc. If the Grantee initiates a request for arbitration or submits a counterclaim to the Company’s request for arbitration, the Grantee shall be required to contribute One Hundred Dollars ($100.00) to those administrative fees and costs, payable to the AAA at the time the Grantee's request for arbitration or counterclaim is submitted. The Company may increase the contribution amount in the future without amending this Agreement, but not to exceed the maximum permitted under the AAA rules then in effect. In all cases, the Grantee and the Company shall be responsible for payment of any fees assessed by the arbitrator as a result of that party’s delay, request for postponement, failure to comply with the arbitrator’s rulings and for other similar reasons. |
(vii) | The Grantee and the Company may choose to be represented by legal counsel in the arbitration process and shall be responsible for their own legal fees, expenses and costs. However, the arbitrator shall have the same authority as a court to order the Grantee or the Company to pay some or all of the other’s legal fees, expenses and costs, in accordance with applicable law. |
(viii) | Unless otherwise agreed, there shall be a single arbitrator, selected by the Grantee and the Company from a list of qualified neutrals furnished by the AAA. If the Grantee and the Company cannot agree on an arbitrator, one will be selected by the AAA. |
(ix) | Unless otherwise agreed, the arbitration hearing will take place in the city where the Grantee works or last worked for the Company. If the Grantee and the Company disagree as to the proper locale, the AAA will decide. |
(x) | The Grantee and the Company shall be entitled to conduct limited pre-hearing discovery. Each may take the deposition of one person and anyone designated by the other as an expert witness. The party taking the deposition shall be responsible for all associated costs, such as the cost of a court reporter and the cost of an original transcript. Each party also has the right to submit one set of ten written questions (including subparts) to the other party, which must be answered under oath, and to request and obtain all documents on which the other party relies in support of its answers to the written questions. Additional discovery may be permitted by the arbitrator upon a showing that it is necessary for that party to have a fair opportunity to present a claim or defense. |
(xi) | The arbitrator shall apply the same substantive law that would apply if the matter were heard by a court and shall have the authority to order the same remedies (but no others) as would be available in a court proceeding. The time limits for requesting arbitration or submitting a counterclaim and the administrative prerequisites for filing an arbitration claim or counterclaim are the same as they would be in a court proceeding. The arbitrator shall consider and decide any dispositive motions (motions seeking a decision on some or all of the claims or counterclaims without an arbitration hearing) filed by any party. |
(xii) | All proceedings, including the arbitration hearing and decision, are private and confidential, unless otherwise required by law. Arbitration decisions may not be published or publicized without the consent of both the Grantee and the Company. |
(xiv) | The arbitrator’s decision is final and binding on the Grantee and the Company. After the arbitrator’s decision is issued, the Grantee or the Company may obtain an order of judgment from a court and may obtain a court order enforcing the decision. The arbitrator’s decision may be appealed to the courts only under the limited circumstances provided by law. |
(xv) | If the Grantee previously signed an agreement, including but not limited to an employment agreement, containing arbitration provisions, those provisions are superseded by the arbitration provisions of this Agreement. |
(xvi) | If any provision of Article VI (e) is found to be void or otherwise unenforceable, in whole or in part, this shall not affect the validity of the remainder of Article VI (e) and the remainder of the Agreement. All other provisions shall remain in full force and effect. |
(f) | Except as provided in connection with mandatory binding arbitration of employment disputes, Grantee hereby submits to the exclusive jurisdiction of the courts of the State of Connecticut and the United States District Court for the District of Connecticut with respect to any action relating to this Agreement, and agrees that (i) the sole and exclusive appropriate venue for any suit or proceeding relating to this Agreement shall be in such court, and (ii) hereby waives any and all objections and defenses based on forum, venue or personal or subject matter jurisdiction as they may relate to a suit or proceeding brought before such court in accordance with the Agreement. |
(a) | Nothing in this Agreement shall interfere with or limit in any way the right of the Company, any Subsidiary or Affiliate to terminate the Grantee’s employment at any time. Neither the execution and delivery hereof nor the granting of the Award shall constitute or be evidence of any agreement or understanding, express or implied, on the part of the Company or any of its Subsidiaries to employ or continue the employment of the Grantee for any period. |
(b) | Until the Restricted Stock Units have become vested, Grantee shall not have any rights as a stockholder (including the right to payment of dividends) by virtue of this grant of Restricted Stock Units. |
(c) | During the Restricted Period, the Restricted Stock Units shall be nontransferable and non-assignable except by will or the laws of descent and distribution. |
(d) | The award will be settled on a net basis. Prior to issuing any Common Shares, the Company will withhold an amount sufficient to satisfy federal, state, local, social security and Medicare withholding tax requirements relating to award. Any social security calculation or other adjustments discovered after net share payment will be settled in cash, not in Shares of Common Stock. Vesting will result in taxable compensation reportable on the Grantee’s W-2 in year of vesting. |
(e) | The Company may from time to time adopt stock ownership requirements applicable to Grantees who are senior managers of the Company. In connection with and for the purpose of implementing those ownership requirements, the Company may adopt certain restrictions on the ability of a Grantee to sell shares issued under this Agreement when such ownership requirements have not been satisfied. Any such restriction on sale will be communicated generally to affected Grantees and the restriction may be modified by the Company from time to time, at its discretion. Neither the Company nor its Board of Directors shall have any obligation or liability to a Grantee in connection with any such restriction. |
(f) | This Restricted Stock Unit is an unfunded obligation of the Company and nothing in this Agreement shall be construed to create any claim against particular assets or require the Company to segregate or otherwise set aside any assets or create any fund to meet its obligations hereunder. |
(g) | Anything herein to the contrary notwithstanding, a Grantee whose Restricted Stock Units have been forfeited as a result of termination of employment due to U.S. Military Service and who is later re-employed (in a full-time active status) after discharge within the time period set in 38 U.S.C. Section 4312 will be eligible to have the forfeited Restricted Stock Units reinstated as follows: (i) if such Grantee is re-employed during the Restricted Period, all forfeited Restricted Stock Units shall be reinstated; or (ii) if such Grantee is re-employed after the Restricted Period, a cash payment will be made to the Grantee, minus applicable taxes, for the value of the forfeited Restricted Stock Units on the Vest Date pursuant to procedures established by the Company for this purpose. |
(h) | If any provision of this Agreement would cause Grantee to incur any additional tax or interest under Section 409A, the Company may reform such provision (including an amendment retroactive to the Effective Date to the extent permissible) to comply with Section 409A. |
(i) | If the Company reasonably anticipates that the Company’s tax deduction with respect to the payment upon vesting of the Restricted Stock Units would be limited or eliminated by application of Section 162(m) of the Internal Revenue Code, the Company may elect, in accordance with Section 409A, to delay the payment of such Restricted Stock Units to the earliest date in which the Company anticipates that its tax deduction for such payment will not be limited or eliminated. |
(j) | This Agreement is subject to the 2010 Stock Incentive Plan heretofore adopted by the Company and approved by its shareholders. The terms and provisions of the Plan (including any subsequent amendments thereto) are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail. |
(k) | Voluntary Deferral. At such times and upon such terms and conditions as the Company shall determine in accordance with the terms of the Plan and Section 409A, the Company may permit eligible Grantees to elect to defer the distribution of an Award otherwise payable to the Grantee under this Agreement until termination of the Grantee’s Employment or such other date Company shall permit. |
(l) | This Agreement is made under and shall be governed by and construed in accordance with the laws of the State of Connecticut, without giving effect to its choice of law provisions. |
(a) | "Affiliate" means an entity at least a majority of the total voting power of the then-outstanding voting securities of which is held, directly or indirectly, by the Company and/or one or more other Affiliates. |
(b) | "Board" means the Board of Directors of Aetna Inc. |
(c) | “Change in Control” means the happening of any of the following: |
(i) | When any “person” as defined in Section 3(a)(9) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and as used in Sections 13(d) and 14(d) thereof, including a “group” as defined in Section 13(d) of the Exchange Act but excluding the Company and any Subsidiary thereof and any employee benefit plan sponsored or maintained by the Company or any Subsidiary (including any trustee of such plan acting as trustee), directly or indirectly, becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act, as amended from time to time), of securities of the Company representing 20 percent or more of the combined voting power of the Company’s then outstanding securities; |
(ii) | When, during any period of 24 consecutive months, the individuals who, at the beginning of such period, constitute the Board (the “Incumbent Directors”) cease for any reason other than death to constitute at least a majority thereof, provided that a director who was not a director at the beginning of such 24-month period shall be deemed to have satisfied such 24-month requirement (and be an Incumbent Director) if such director was elected by, or on the recommendation of or with the approval of, at least two-thirds of the directors who then qualified as Incumbent Directors either actually (because they were directors at the beginning of such 24-month period) or by prior operation of this paragraph (ii); or |
(iii) | The occurrence of a transaction requiring stockholder approval for the acquisition of the Company by an entity other than the Company or a Subsidiary through purchase of assets, or by merger, or otherwise. |
(d) | "Committee" means the Board's Committee on Compensation and Organization or any successor thereto. |
(e) | "Common Stock" means shares of the Company's Common Stock, $.01 par value per share. |
(f) | "Company" means Aetna Inc. |
(g) | "Effective Date” means the date of grant of this Stock Appreciation Right, as approved by the Committee. |
(h) | “Exercise Date” means the date the Grantee has notified the designated broker to exercise all or a portion of the Stock Appreciation Right. |
(i) | "Fair Market Value" means the closing price of the Common Stock as reported by the Consolidated Tape of the New York Stock Exchange Listed Shares on the date such value is to be determined, or, if no shares were traded on such day, on the next day on which the Common Stock is traded. |
(j) | “Fundamental Corporate Event” shall mean any stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares, warrants or rights offering to purchase Common Stock at a price substantially below fair market value, or similar event. |
(k) | “Grantee” means the person to whom this Stock Appreciation Right has been granted. |
(l) | “Grant Price” means the dollar amount per share of Common Stock that is the basis for determining the appreciation in value of the Common Stock. |
(m) | “Holding Company” means an entity that becomes a holding company for the Company or its businesses as a part of any reorganization, merger, consolidation or other transaction, provided that the outstanding shares of common stock of such entity and the combined voting power of the then outstanding voting securities of such entity entitled to vote generally in the election of directors is, immediately after such reorganization, merger, consolidation or other transaction, beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively of the voting stock outstanding immediately prior to such reorganization, merger, consolidation or other transaction in substantially the same proportions as |
(n) | "Long Term Disability" means long-term disability as defined under the terms of the Company's applicable long-term disability plans or policies. |
(o) | "Plan" means the Aetna Inc. 2010 Stock Incentive Plan. |
(p) | "Retirement" means the termination of employment of a Grantee from active service with the Company, a Subsidiary or Affiliate provided the Grantee’s age and completed years of service total 65 or more points at termination of employment. |
(q) | “SAR” means Stock Appreciation Right. |
(r) | "Shares Granted" means the number of shares of Common Stock represented by the Stock Appreciation Right, or such other amount as may result by operation of Article IV of this Agreement. |
(s) | "Shares of Stock" or "Stock" means the Common Stock. |
(t) | “Stock Appreciation Right” or “SAR” means the right granted herein to be paid the excess, as of the Exercise Date, of (i) the Fair Market Value of the shares of Common Stock associated with this Stock Appreciation Right (or the portion thereof that is surrendered on exercise) over (ii) the Grant Price of such Stock Appreciation Right. |
(u) | “Stock Appreciation Rights Vested” means number of Stock Appreciation Rights exercisable on any given date. |
(v) | "Subsidiary" means any entity of which, at the time such subsidiary status is to be determined, at least 50% of the total combined voting power of all classes of stock in such entity is held by the Company and/or one or more other subsidiaries. |
(w) | "Successor" means the legal representative of the estate of a deceased Grantee or the person or persons who shall acquire the right to exercise a SAR by bequest or inheritance or by reason of the death of the Grantee. |
(x) | "Term" means the period during which the SAR granted hereby may be exercised. |
(y) | “Vest Date” means the date on which a portion of the SAR becomes exercisable pursuant to the Terms of the Award and, as set forth on the website of the designated broker and in the Notice of Stock Appreciation Right Grant, if applicable. |
(a) | Subject to the terms of this Agreement, the term of the SAR shall commence on the first Vest Date and shall terminate, unless sooner terminated by the terms of the Plan or this Terms of Award Agreement, at: |
(i) | The close of the Company's business on the day preceding the tenth anniversary of the Effective Date, if the Company is open for business on such day; or |
(ii) | The close of the Company's business on the next preceding day that the Company is open for business. |
(b) | The SAR is exercisable in installments, each installment to become exercisable as of the Vest Date in accordance with the terms of the Plan and this Terms of Award Agreement. Once an installment is vested, it may be exercised in whole or in part only during the Term of the SAR. |
(a) | Except as provided in (d) below, if the Grantee shall die or begin to receive Long Term Disability benefits after the Effective Date, the SAR shall become vested and immediately exercisable and the Grantee or Successor of the Grantee may exercise the SAR until the earlier of: |
(i) | The expiration of the Term of the SAR; or |
(ii) | A period not to exceed five years following such death or commencement of Long Term Disability benefits. |
(b) | Except as provided in (e) below, if Grantee shall, for reason of Retirement, cease to be employed by the Company, its Subsidiaries or Affiliates after the Effective Date, the Grantee will become immediately vested and may immediately exercise any SAR that would have otherwise become vested within one year from the Grantee’s termination of employment, and the Grantee or Successor of the Grantee may exercise a vested SAR until the earlier of: |
(i) | The expiration of the Term of the SAR; or |
(ii) | A period not to exceed five years following such cessation of employment. |
(c) | Except as provided in (d) and (e) below, if the Grantee shall, for a reason other than death, Long Term Disability or Retirement, cease to be employed by the Company, its Subsidiaries or Affiliates during the Term of the SAR, the Grantee may exercise a vested SAR until the earlier of: |
(i) | The expiration of the term of the SAR; or |
(ii) | A period not to exceed ninety days following such cessation of employment. |
(d) | Except as provided in (a) or (b) above, any SAR, or portion of a SAR that has not become vested and exercisable at the time of cessation of employment shall terminate immediately upon such cessation of employment and may not be exercised thereafter. Provided, however, if Grantee’s employment is terminated by the Company other than for cause and Grantee has not previously, or does not subsequently, vest to any portion of the SAR in accordance with its terms, then upon the forfeiture of the entire SAR, the Company shall pay Grantee an amount equal to the SAR value on a single share of Common Stock, whether or not the forfeited SAR related to more than a single share of Common Stock, calculated as of the date of termination of employment under the same |
(e) | No SAR may vest or be exercised after the Company has terminated the employment of the Grantee for cause, except that the Committee may, in its sole discretion, permit the exercise of a vested SAR for a period of up to ninety days in cases where the Committee shall determine such exercise period is warranted under the particular circumstances. In addition, the Company may terminate the SAR if Grantee has willfully engaged in gross misconduct or other serious impropriety which the Company determines is likely to be damaging or detrimental to the Company, any Subsidiary or Affiliate. |
(f) | Employment for purposes of determining the vesting rights of the Grantee and expiration date of the grant under this Article VI shall mean continuous full-time salaried employment with the Company, a Subsidiary or an Affiliate, except that the period during which the Grantee is on vacation, sick leave, or other pre-approved leave of absence (provided there is no actual termination of employment), or in receipt of salary continuation or severance pay shall not interrupt the continuous employment of the Grantee. Employment shall also include service with Aetna Foundation, Inc. |
(g) | Except as otherwise herein provided, exercise of the SAR, whether by the Grantee or the Successor of the Grantee, shall be subject to all terms and conditions of this Agreement. |
(a) | Grantee understands that the Grantee shall not have any rights as stockholder by virtue of the grant of an SAR but only with respect to shares of Common Stock actually issued to the Grantee in accordance with the terms hereof. |
(b) | Anything herein to the contrary notwithstanding, the Company may postpone the exercise of the SAR or any portion thereof for such time as the Committee in its discretion may deem necessary, in order to permit the Company with reasonable diligence (i) to effect or maintain registration under the Securities Act of 1933, as amended, of the Plan or the shares of Common Stock issuable upon the exercise of the SAR or (ii) to determine that the Plan and such shares are exempt from registration; and the Company shall not be obligated by virtue of this Agreement or any provision of the Plan to recognize the exercise of the SAR or to sell or issue shares of Common Stock in violation of said Act or of the law of any government having jurisdiction thereof. Any such postponement shall not extend the Term of the SAR; and neither the Company nor its Board shall have any obligation or liability to the Grantee, or to the Grantee's Successor, with respect to any shares of Common Stock as to which the SAR shall lapse because of such postponement. |
(c) | The SAR shall be nontransferable and nonassignable except by will and by the laws of descent and distribution. During the Grantee's lifetime, the SAR may be exercised only by the Grantee. |
(d) | The SAR is not an incentive stock option as described in the Internal Revenue Code of 1986, as amended, Section 422A (b). |
(e) | This Agreement is subject to the 2010 Stock Incentive Plan heretofore adopted by the Company and approved by its shareholders. The terms and provisions of the Plan (including any subsequent amendments thereto) are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail. |
(f) | Anything herein to the contrary notwithstanding, a Grantee whose SAR has been forfeited as a result of termination of employment due to U.S. Military Service and who is later re-employed (in a full-time active status) after discharge within the time period set in 38 U.S.C. Section 4312 will be eligible to have the forfeited SAR reinstated for the original Term pursuant to procedures established by the Company for this purpose. |
(g) | Nothing in this Agreement shall interfere with a limit in anyway the right of the Company or any Subsidiary or Affiliate to terminate the Grantee’s employment at any time. Neither the execution and delivery of this Agreement nor the granting of the SAR shall constitute or be evidence of any agreement or understanding, express or implied, on the part of the Company or any of its Subsidiaries to employ Grantee for any period. |
(h) | This SAR is an unfunded obligation of the Company and nothing in this Agreement shall be construed to create any claim against particular assets or require the Company to segregate or otherwise set aside any assets or create any fund to meet its obligations hereunder. |
(i) | The Company shall have the power to withhold, an amount sufficient to satisfy Federal, state and local, social security and medicare withholding tax requirements, if applicable. Any social security calculation or other adjustments discovered after the net share payment will be settled in cash, not in Common Stock. |
(j) | The Company may from time to time adopt stock ownership requirements applicable to Grantees who are senior managers of the Company. In connection with and for the purpose of implementing those ownership requirements, the Company may adopt certain restrictions on the ability of a Grantee to sell shares issued under this Agreement when such ownership requirements have not been satisfied. Any such restriction on sale will be communicated generally to affected Grantees and the restriction may be modified by the Company from time to time, at its discretion. Neither the Company nor its Board of Directors shall have any obligation or liability to a Grantee in connections with any such restriction. |
(k) | This Agreement is made under and shall be governed by and construed in accordance with the laws of the State of Connecticut, without giving effect to its choice of law provisions. |
(a) | As consideration for the grant of the SAR, without prior written consent of the Company: |
(i) | Grantee will not (except to the extent required by an order of a court having competent jurisdiction or under subpoena from an appropriate government agency) use or disclose to any third person, whether during or subsequent to Grantee’s Employment, any trade secrets, confidential information and proprietary materials, which may include, but are not limited to, the following categories of information and materials: customer lists and identities; provider lists and identities; employee lists and identities; product development and related information; marketing plans and related information; sales plans and related information; premium or other pricing information; operating policies and manuals; research; payment rates; methodologies; procedures; contractual forms; business plans; financial records; computer programs; database; or other financial, commercial, business or technical information related to the Company, any Subsidiary or Affiliate unless such information has been previously disclosed to the public by the Company or has become public knowledge other than by a breach of this Agreement (“Confidential Information”); provided, however, that this limitation shall not apply to any such use or disclosure made while Grantee is employed by the Company, any Subsidiary or Affiliate if such disclosure occurred in connection with the performance of Grantee’s job as an employee of the Company, any Subsidiary or Affiliate; |
(ii) | Grantee will not, during and for a period of twelve (12) months following Grantee’s termination of employment, directly or indirectly, (x) engage in the ownership (except less than 1% of the outstanding capital stock of any publicly traded company) of or, (y) become an employee of, or (z) act as a consultant or contractor to, any competitor of the Company (“Competitor”) in any market in the United States where Company, Affiliate or Subsidiary does business. |
a. | For purposes of this paragraph “Competitor” shall mean any entity, organization, person or corporation that is involved in the same business as Company, Subsidiary or Affiliate, but in the case of (y) and (z), only to the extent such work, consulting or other activity on behalf of other entity, organization, person or corporation |
i. | is materially similar to the duties and/or functions that Grantee performed for the Company, Subsidiary or Affiliate in the last 12 months or involves duties and/or functions for Competitor about which Grantee has Confidential Information in the last 12 months. Notwithstanding |
1. | with respect to sales functions for the Company, Subsidiary or Affiliate that are regionally based or whose focus is geographically limited, the restriction shall only apply where such work, consulting or other activity on behalf of a Competitor overlaps in whole or in part the same geographic area in which the Grantee worked for Company, Subsidiary or Affiliate in the last 12 months; |
2. | with respect to corporate staff functions, the restriction shall only apply where Competitor is substantially engaged in the business of health insurance, managed health care, population health management, or related products or services. |
b. | Notwithstanding, if Grantee’s employment is terminated by the Company, Subsidiary or Affiliate other than for cause, the length of the noncompetition covenant in this paragraph shall not exceed the length of the severance and/or salary continuation benefits paid by the Company, Subsidiary or Affiliate to Grantee. |
c. | Grantee acknowledges and agrees that these restrictions: |
i. | are necessary to protect the Confidential Information and goodwill of the Company, Subsidiary or Affiliate; |
ii. | are appropriately tailored and limited in time and geographic scope to do so; and |
iii. | do not impair or limit the Grantee’s ability to earn a living. |
(iii) | Grantee will not, during and for a period of 24 months following Grantee’s termination of Employment, directly or indirectly induce or attempt to induce any employee of the Company, and Subsidiary or Affiliate to be employed or perform services elsewhere; |
(iv) | Grantee will not, during and for a period of 24 months following Grantee's termination of Employment, directly or indirectly, induce or attempt to induce any agent or agency, broker, supplier or health care provider of the Company, any Subsidiary or Affiliate to cease or curtail providing services to the Company, any Subsidiary or Affiliate; and |
(v) | Grantee will not, during and for a period of 24 months following Grantee’s termination of Employment, directly or indirectly solicit or attempt to solicit the trade of any individual or entity which, at the time of such solicitation, is a customer of the Company, any Subsidiary or Affiliate, or which the Company, any Subsidiary or Affiliate is undertaking reasonable steps to procure as a customer at the time of or immediately preceding termination of Employment; provided, however, that this limitation shall only apply to any product or service which is in competition with a product or service of the Company, any Subsidiary or Affiliate and shall apply only with respect to a customer or prospective customer with whom the Grantee has been directly or indirectly involved |
(vi) | Grantee will not, during and for a period of 24 months following Grantee’s termination of Employment, for himself or herself or on behalf of or in cooperation with any other person or entity, consult with or in any manner provide advice to, any individual or entity which is a customer of the Company or any Subsidiary or Affiliate of the Company, provided, however, that this limitation shall apply only to consultation or advice relating to any product or service of the Company, or any Subsidiary or Affiliate, or which is in competition with any product or service of the Company, or any Subsidiary or Affiliate, and shall apply only with respect to a customer or prospective customer with whom the Grantee has been directly or indirectly involved, or about which Grantee has Confidential Information. |
(viii) | Grantee shall promptly notify the Company’s General Counsel if Grantee is contacted by a regulatory or self-regulatory agency with respect to matters pertaining to the Company or by an attorney or other individual who informs the Grantee that he/she has filed, intends to file, or is considering filing a claim or complaint against the Company. |
(ix) | Grantee acknowledges that all original works of authorship that are created by Grantee (solely or jointly with others) within the scope of Grantee’s employment and relating in any way to the business or contemplated business, products, activities, research or development of the Company, any Subsidiary or Affiliate, or resulting from any work performed by the Grantee for the Company, any Subsidiary or Affiliate (in each case, regardless of when or where the work product is prepared or whose equipment or other resources is used in preparing the same) which are protectable by copyright are “works made for hire” as that term is defined in the United States Copyright Act (17 U.S.C., Section 101). To the extent that the foregoing does not apply, the Grantee hereby irrevocably assigns to the Company, and its successors and assigns, for no additional consideration, the Grantee’s entire right, title and interest in and to all such works of authorship. Grantee further acknowledges that while employed by the Company, any Subsidiary or Affiliate, Grantee may develop ideas, inventions, discoveries, innovations, procedures, methods, know-how or other works which relate to the Company’s current or are reasonably expected to relate to the Company’s future business (in each case, regardless of when or where the work product is prepared or whose equipment or other resources is used in preparing the same) that may be patentable or subject to trade secret protection. Grantee agrees that all such works of authorship, ideas, inventions, discoveries, innovations, procedures, methods, know-how and other works shall belong exclusively to the Company and the Grantee hereby assigns all right, title and interest therein to the Company. |
(b) | If any provision of Article VIII (a) is determined by a court of competent jurisdiction not to be enforceable in the manner set forth herein, the Company and Grantee agree that it is the intention of the parties that such provision should be enforceable to the maximum extent possible under applicable law and that such court shall reform such provision to make it enforceable in accordance with the intent of the parties. |
(c) | Grantee acknowledges that a material part of the inducement for the Company to grant the SAR is Grantee’s covenants set forth in Article VIII(a) and that the covenants and obligations of Grantee with respect to nondisclosure, nonsolicitation, cooperation and intellectual property rights relate to special, unique and extraordinary matters and that a violation of any of the terms of such covenants and obligations will cause the Company irreparable injury for which adequate remedies are not available at law. Therefore, Grantee agrees that, if Grantee shall breach any of those covenants or obligations, Grantee shall not be entitled to exercise the SAR or be entitled to retain any income therefrom and the Company shall be entitled to an injunction, restraining order or such other equitable relief (without the requirement to post bond) restraining Grantee from committing any violation of the covenants and obligations contained in Article VIII. The Company also shall be entitled to recover any attorneys’ fees, costs, and expenses it incurs in connection with any judicial proceeding arising out of Grantee’s breach of this Agreement. The remedies in the preceding sentences are cumulative and are in addition to any other rights and remedies the Company may have at law or in equity as a court or arbitrator shall reasonably determine.. |
(d) | The Restrictive Covenants set forth in this Article VIII shall supplement and do not supersede the restrictions agreed to by Grantee in any other agreement or contact. |
(e) | Employment Dispute Arbitration Program - Mandatory Binding Arbitration of Employment Disputes. |
(i) | Except as otherwise specified in this Agreement, the Grantee and the Company agree that all employment-related legal disputes between them will be submitted to and resolved by binding arbitration, and neither the Grantee nor the Company will file or participate as an individual party or member of a class in a lawsuit in any court against the other with respect to such matters. This shall apply to claims brought on or after the date the Grantee accepts this Agreement, even if the facts and circumstances relating to the claim occurred prior to that date and regardless of whether Grantee or the Company previously filed a complaint/charge with a government agency concerning the claim. |
(ii) | THE GRANTEE UNDERSTANDS THAT THE ARBITRATION PROVISIONS OF THIS AGREEMENT AFFECT THE LEGAL RIGHTS OF THE GRANTEE AND THE COMPANY AND ACKNOWLEDGES THAT THE GRANTEE HAS BEEN ADVISED TO, AND HAS BEEN GIVEN THE OPPORTUNITY TO, OBTAIN LEGAL ADVICE BEFORE SIGNING THIS AGREEMENT. |
(iii) | Article VIII (e) of this Agreement does not apply to workers’ compensation claims, unemployment compensation claims, and claims under the Employee Retirement Income Security Act of 1974 (“ERISA”) for employee benefits. A dispute as to whether Article VIII (e) of this Agreement applies must be submitted to the binding arbitration process set forth in this Agreement. |
(iv) | The Grantee and/or the Company may seek emergency or temporary injunctive relief from a court (including with respect to claims arising out of Article VIII (a) in accordance with applicable law). However, except as provided in Article VIII (c) of this Agreement, after the court has issued a ruling concerning the emergency or temporary injunctive relief, the Grantee and the Company shall be required to submit the dispute to binding arbitration pursuant to this Agreement. |
(v) | Unless otherwise agreed, the arbitration will be administered by the American Arbitration Association (the “AAA”) and will be conducted pursuant to the AAA’s Employment Arbitration Rules and Mediation Procedures (the “Rules”), as modified in this Agreement, in effect at the time the request for arbitration is filed. The AAA’s Rules are available on the AAA’s website at www.adr.org. THE GRANTEE ACKNOWLEDGES THAT THE COMPANY HAS ENCOURAGED THE GRANTEE TO READ THESE RULES PROMPTLY AND CAREFULLY AND THAT THE GRANTEE HAS BEEN AFFORDED SUFFICIENT OPPORTUNITY TO DO SO. |
(vi) | If the Company initiates a request for arbitration, the Company will pay all of the administrative fees and costs charged by the AAA, including the arbitrator’s compensation and charges for hearing room rentals, etc. If the Grantee initiates a request for arbitration or submits a counterclaim to the Company’s request for arbitration, the Grantee shall be required to contribute One Hundred Dollars ($100.00) to those administrative fees and costs, payable to the AAA at the time the Grantee's request for arbitration or counterclaim is submitted. The Company may increase the contribution amount in the future without amending this Agreement, but not to exceed the maximum permitted under the AAA rules then in effect. In all cases, the Grantee and the Company shall be responsible for payment of any fees assessed by the arbitrator as a result of that party’s delay, request for postponement, failure to comply with the arbitrator’s rulings and for other similar reasons. |
(vii) | The Grantee and the Company may choose to be represented by legal counsel in the arbitration process and shall be responsible for their own legal fees, expenses and costs. However, the arbitrator shall have the same authority as a court to order the Grantee or the Company to pay some or all of the other’s legal fees, expenses and costs, in accordance with applicable law. |
(viii) | Unless otherwise agreed, there shall be a single arbitrator, selected by the Grantee and the Company from a list of qualified neutrals furnished by the AAA. If the Grantee and the Company cannot agree on an arbitrator, one will be selected by the AAA. |
(ix) | Unless otherwise agreed, the arbitration hearing will take place in the city where the Grantee works or last worked for the Company. If the Grantee and the Company disagree as to the proper locale, the AAA will decide. |
(x) | The Grantee and the Company shall be entitled to conduct limited pre-hearing discovery. Each may take the deposition of one person and anyone designated by the other as an expert witness. The party taking the deposition shall be responsible for all associated costs, such as the cost of a court reporter and the cost of an original transcript. Each party also has the right to submit one set of ten written questions (including subparts) to the other party, which must be answered under oath, and to request and obtain all documents on which the other party relies in support of its answers to the written questions. Additional discovery may be permitted by the arbitrator upon a showing that it is necessary for that party to have a fair opportunity to present a claim or defense. |
(xi) | The arbitrator shall apply the same substantive law that would apply if the matter were heard by a court and shall have the authority to order the same remedies (but no others) as would be available in a court proceeding. The time limits for requesting arbitration or submitting a counterclaim and the administrative prerequisites for filing an arbitration claim or counterclaim are the same as they would be in a court proceeding. The arbitrator shall consider and decide any dispositive motions (motions seeking a decision on some or all of the claims or counterclaims without an arbitration hearing) filed by any party. |
(xii) | All proceedings, including the arbitration hearing and decision, are private and confidential, unless otherwise required by law. Arbitration decisions may not be published or publicized without the consent of both the Grantee and the Company. |
(xiii) | Unless otherwise agreed, the arbitrator’s decision will be in writing with a brief summary of the arbitrator’s opinion. |
(xiv) | The arbitrator’s decision is final and binding on the Grantee and the Company. After the arbitrator’s decision is issued, the Grantee or the Company may obtain an order of judgment from a court and may obtain a court order enforcing the decision. The arbitrator’s decision may be appealed to the courts only under the limited circumstances provided by law. |
(xv) | If the Grantee previously signed an agreement, including but not limited to an employment agreement, containing arbitration provisions, those provisions are superseded by the arbitration provisions of this Agreement. |
(xvi) | If any provision of Article VIII (e) is found to be void or otherwise unenforceable, in whole or in part, this shall not affect the validity of the remainder of Article VIII (e) and the remainder of the Agreement. All other provisions shall remain in full force and effect. |
(f) | Except as provided in connection with mandatory binding arbitration of employment disputes, Grantee hereby submits to the exclusive jurisdiction of the courts of the State of Connecticut and the United States District Court for the District of Connecticut with respect to any action relating to this Agreement, and agrees that (i) the sole and exclusive appropriate venue for any suit or proceeding relating to this Agreement shall be in such court, and (ii) hereby waives any and all objections and defenses based on forum, venue or personal or subject matter jurisdiction as they may relate to a suit or proceeding brought before such court in accordance with the Agreement. |
Three Months Ended | Years Ended December 31, | |||||||||||||||||
(Millions) | March 31, 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | ||||||||||||
Income from continuing operations before income taxes | $ | 1,365.6 | $ | 3,496.6 | $ | 2,936.9 | $ | 2,545.4 | $ | 3,077.8 | $ | 2,644.2 | ||||||
Add back fixed charges | 93.7 | 391.4 | 393.2 | 318.6 | 293.6 | 307.7 | ||||||||||||
Income as adjusted ("earnings") | $ | 1,459.3 | $ | 3,888.0 | $ | 3,330.1 | $ | 2,864.0 | $ | 3,371.4 | $ | 2,951.9 | ||||||
Fixed charges: | ||||||||||||||||||
Interest expense | $ | 79.0 | $ | 329.3 | $ | 333.7 | $ | 268.8 | $ | 246.9 | $ | 254.6 | ||||||
Portion of rents representative of interest factor | 14.7 | 62.1 | 59.5 | 49.8 | 46.7 | 53.1 | ||||||||||||
Total fixed charges | $ | 93.7 | $ | 391.4 | $ | 393.2 | $ | 318.6 | $ | 293.6 | $ | 307.7 | ||||||
Ratio of earnings to fixed charges | 15.57 | 9.93 | 8.47 | 8.99 | 11.48 | 9.59 |
1. | I have reviewed this quarterly report on Form 10-Q of Aetna Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: | April 28, 2015 | /s/ Mark T. Bertolini |
Mark T. Bertolini | ||
Chairman and Chief Executive Officer |
1. | I have reviewed this quarterly report on Form 10-Q of Aetna Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: | April 28, 2015 | /s/ Shawn M. Guertin |
Shawn M. Guertin | ||
Executive Vice President and Chief Financial Officer |
Date: | April 28, 2015 | /s/ Mark T. Bertolini |
Mark T. Bertolini | ||
Chairman and Chief Executive Officer |
Date: | April 28, 2015 | /s/ Shawn M. Guertin |
Shawn M. Guertin | ||
Executive Vice President and Chief Financial Officer |
D!\@'Z`@,"#`(4`AT")@(O
M`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#
M%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@
M!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%#044%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1
M!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(
M@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4
M"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,
M=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV
M#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$1
M3Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&
M%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7
M'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1
M&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A
M( &YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]
M07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6K
MA@Z& '!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ .=^99KNZA3<#%
M"LC*!&H7`)'Q4+>7\71TH_@O\)XX$IU^(/QA,<<2PJTG0W5LLY14"`O4R[6>
MIDE(',C.7)Y))Y]A0\X0!YJ
M'I0>OA[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B--@U$S5--80!YJ'I0>OA[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$A
MSB'[(B0U9J5"(/B<_(#@*C4
MQ"@U(Z-MDVBYWSZ\A2PT^?VMN!8IZV/9^\DH
MU2@GK:C'0/-15\"015RP3`P0/%I;(_V_]P;;G*"6VN(5AWF%:N@-5=>&M*Y`
M!PRFI6HR0<3-RCS?#S)%)#-&(MRC%64'M9>&I:YI7!!K2HR:]52^Y(Z&G7O?
MNO=>]^Z]U:]_)4[3J^L_Y@O5%`*F:##]IXG>75^?2%G_`,H@R^WZO/X&&2(,
MJRQ_WSVUC"VKA%!<7*@&-O=G;EW#DG
&WC'ZDCA1]K&@_F>O
MF>]D;[SO:786^NR]T3FIW'V#N_W46-GBJ:B.CIY(:[L
M#;U++'/5S34\-+"Z2D/(\B*BW8L`+@FYBD,7+^^RJ2&6SF.!4XC8\,U^RG1;
MO#E-HW5QQ%M*?7@C>77T@:7=VU*ZHBI*+<^WJRJG?QP4U+FL;45$SD$A(H8J
MEY)'('T`)]X(-;7**6>W<*/,J0/\'6*C03J"S0N%'J#TTY[LSK?:L%75;H[`
MV1MNEQ\DT5?4Y[=>!P\%%+3B5JB*KFR%?3QTTD`@
B./@,/VX_R]?0S]X0=8O]>]^Z]U[W[KW7O?NO=>]^Z]U_
M_]/81_X402.GPIZS5'=5E^4&R8Y55BHD0=5=TRA)`"`Z"2-6L>-2@_4#W,OL
M<`>;=PJ/^6=)_P!7H.I(]K@/ZP7?_/&__5R+K3.]Y5=3UU[W[KW7O?NO=;-G
M_";G!8:HW5\MMRSK&=PXC;_36"Q;EXA*N&W%D>RLAGE2,KYFC>NVOC2Q4A5*
MJ&!)6V/WOS-*MMRS;@_H,\['_3*(@O\`)VZB/W7DD$.R1#^R9I2?M41@?R9N
MMJSWCCU#/7O?NO=:N?\`PI/_`.Y,/_+B_P#YA/O(?V$_YVO_`*A?^UCJ8?:?
M_EO_`/-C_K-UJY^\B.IAZ][]U[KWOW7NMMW_`(3C_P#,E?DA_P")1VI_[R